hydroxychloroquine has been researched along with Pregnancy in 247 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This double-blind placebo-controlled study investigated the effect of hydroxychloroquine on pregnancy outcomes in people with unexplained recurrent pregnancy loss (URPL)." | 9.51 | The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study "pilot study". ( Abiri, A; Dehpour, AR; Moini, A; Pirjani, R; Rabiei, M; Sepidarkish, M, 2022) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 9.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 9.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety." | 9.09 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. ( Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 9.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 8.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 8.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS." | 8.91 | The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. ( Alijotas-Reig, J; Andreoli, L; Benbara, A; Bertero, T; Bezanahary, H; Bremme, K; Canti, V; Carbillon, L; Dhote, R; Fain, O; Kuzenko, A; Lazzaroni, MG; Levy, P; Maurier, F; Mekinian, A; Nicaise-Roland, P; Ruffatti, A; Tigazin, A; Tincani, A, 2015) |
| " We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment." | 8.91 | Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? ( Botta, A; De Carolis, MP; De Carolis, S; Del Sordo, G; di Pasquo, E; Garufi, C; Lanzone, A; Salvi, S, 2015) |
| "Hydroxychloroquine combined with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines." | 8.31 | Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. ( Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 8.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "Does hydroxychloroquine (HCQ) improve pregnancy outcomes after frozen embryo transfer (FET) cycles in patients who are positive for autoantibodies？ METHOD OF STUDY: This was a retrospective clinical study involving 128 patients who were positive for autoantibodies undergoing FET cycles between October 2017 and December 2022." | 8.31 | Hydroxychloroquine improves pregnancy outcomes in patients undergoing frozen embryo transfer with positive serum autoantibodies. ( Guo, Y; Ji, H; Ling, X; Shen, R; Su, Y; Zhang, M; Zhao, C, 2023) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 8.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| "Hydroxychloroquine is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity." | 8.02 | Hydroxychloroquine early in pregnancy and risk of birth defects. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Straub, L; Zhu, Y, 2021) |
| "Among pregnancies exposed to 4-aminoquinolines (chloroquine and HCQ), no increased risk of major birth defects, preterm birth, or SGA was identified." | 8.02 | Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. ( Andersen, JT; Andersson, NW; Skov, L, 2021) |
| "Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS." | 8.02 | The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. ( Alvarez, R; Balparda, J; Beruti, E; Fernandez Suarez, C; Gerde, M; Heer, C; Ibarra, E; Iglesias, M; Mac Kenzie, R; Rubinstein, F, 2021) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 7.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Secondly, we estimated the prevalence of AVB among mothers with anti-Ro/La antibodies and examined the relationship of those fetal AVB with mother's use of hydroxychloroquine during pregnancy." | 7.91 | Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. ( Catoggio, LJ; Mollerach, FB; Rosa, J; Scolnik, M; Soriano, ER, 2019) |
| "This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy." | 7.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 7.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "To evaluate pregnancy safety of hydroxychloroquine (HCQ) for rheumatologic diseases." | 7.79 | Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. ( Blyakhman, S; Diav-Citrin, O; Ornoy, A; Shechtman, S, 2013) |
| "To determine the effect of hydroxychloroquine treatment during pregnancy and lactation on babies of mothers affected by rheumatic diseases." | 7.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 7.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ)." | 7.69 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. ( Buchanan, NM; Hughes, GR; Kerslake, S; Khamashta, MA; Lima, F; Toubi, E, 1996) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 7.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies." | 7.01 | Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. ( Bacal, V; Bedaiwy, MA; Hooper, A, 2023) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 6.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| " Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy." | 6.47 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. ( Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011) |
| " HCQ is generally safe and may be prescribed to pregnant women." | 5.91 | Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Kaneko, K; Murashima, A; Sago, H; Tanaka, R; Tsurane, K; Yoshida, K, 2023) |
| "Hydroxychloroquine (HCQ) was originally used as an anti-malaria drug and has now shown benefit in refractory OAPS where conventional treatment has failed, with the expectation of providing protective clinical benefits for both the mother and foetus." | 5.72 | Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. ( Hu, M; Liu, J; Song, S; Tian, Y; Wan, S; Wang, X; Xia, Y; Zhang, L; Zhang, M; Zhou, Q, 2022) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 5.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "The pregnancy is still ongoing without any visible sequelae on the foetus so far." | 5.56 | COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report. ( Calès, P; Delaroche, L; Descamps, P; Dieli-Crimi, R; Guerin, A; Lamazou, F; Letouzey, V; Octernaud, S; Oger, P; Place, V, 2020) |
| "This double-blind placebo-controlled study investigated the effect of hydroxychloroquine on pregnancy outcomes in people with unexplained recurrent pregnancy loss (URPL)." | 5.51 | The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study "pilot study". ( Abiri, A; Dehpour, AR; Moini, A; Pirjani, R; Rabiei, M; Sepidarkish, M, 2022) |
| "Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares." | 5.51 | Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| " The HCQ group showed a trend towards lower dosage of prednisone (OR 0." | 5.46 | Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. ( de Hair, MJH; Derksen, RHWM; Fritsch-Stork, RDE; Kroese, SJ; Lely, AT; Limper, M; van Laar, JM, 2017) |
| "Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the historical 18% recurrence rate of CHB." | 5.34 | Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. ( Buyon, JP; Clancy, R; Cohen, RE; Copel, JA; Costedoat-Chalumeau, N; Cuneo, BF; Friedman, DM; Izmirly, P; Kim, M; Masson, M; Phoon, CKL; Robins, K; Saxena, A; Wainwright, BJ; Zahr, N, 2020) |
| "Forty-five ECGs were available for corrected QT interval (QTc) measurement, and levels of hydroxychloroquine were assessed during each trimester of pregnancy and in the cord blood, providing unambiguous assurance of drug exposure." | 5.34 | Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. ( Buyon, JP; Clancy, R; Cohen, R; Copel, J; Costedoat-Chalumeau, N; Cuneo, BF; Friedman, DM; Izmirly, PM; Kim, M; Masson, M; Phoon, CK; Saxena, A; Wainwright, BJ; Zahr, N, 2020) |
| "Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus." | 5.29 | The use of hydroxychloroquine in lupus pregnancy: the British experience. ( Buchanan, NM; Hughes, GR; Khamashta, MA, 1996) |
| "Multiple guidelines recommend continuing hydroxychloroquine (HCQ) for SLE during pregnancy based on observational data." | 5.22 | Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. ( Balevic, S; Bay, C; Clowse, MEB; Eudy, AM; Fischer-Betz, R; Gladman, DD; Kosinski, A; Mokbel, A; Molad, Y; Nalli, C; Petri, M; Sanders-Schmidler, G; Tincani, A; Urowitz, M; van Noord, M, 2022) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 5.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| " Ulipristal for uterine fibroids : market withdrawal due to risk of severe liver injury." | 5.12 | [Pharmacovigilance update]. ( Ekobena, P; Ivanyuk, A; Livio, F, 2021) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 5.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "The use of hydroxychloroquine (HCQ) in pregnancy remains controversial." | 5.10 | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. ( Amoura, Z; Costedoat-Chalumeau, N; Denjoy, I; Duhaut, P; Huong, DL; Lupoglazoff, JM; Piette, JC; Sebbough, D; Vauthier, D; Wechsler, B, 2003) |
| "We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety." | 5.09 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. ( Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001) |
| ", chloroquine and hydroxychloroquine, in pregnant patients with lupus who continued antimalarial drugs throughout pregnancy." | 5.08 | Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. ( Parke, A; West, B, 1996) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 5.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| "Current research in the field of systemic lupus erythematosus (SLE) and pregnancy focuses on predictors of adverse pregnancy outcomes, the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy and the importance of preconception counselling." | 5.05 | [Pregnancy with lupus erythematosus-an update]. ( Fischer-Betz, R; Haase, I, 2020) |
| "Hydroxychloroquine (HCQ) is used in the treatment of rheumatologic diseases including systemic lupus erythematosus, rheumatoid arthritis and other conditions." | 5.05 | [Hydroxychloroquine treatment rarely causes eye damage when used correctly]. ( Andersen, J; Bay-Laurberg, T; Clemmensen, K; Deleuran, B; Troldborg, A, 2020) |
| "This review summarizes recent research in the field of systemic lupus erythematosus (SLE) and pregnancy with focus on clinical and biochemical predictors of adverse pregnancy outcomes (APOs), accumulating evidence for the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy, and the importance of preconception counseling." | 5.01 | Update on pregnancy complications in systemic lupus erythematosus. ( Marder, W, 2019) |
| " Hydroxychloroquine (HCQ) appears protective against flares in pregnancy, neonatal congenital heart block and preterm birth." | 5.01 | Systemic lupus erythematosus in pregnancy: high risk, high reward. ( Do, SC; Druzin, ML, 2019) |
| "Hydroxychloroquine (HCQ), a toll like receptor (TLR) 7 and 9 antagonist, is used during pregnancy for inflammatory conditions with limited understanding of its placental toxicology." | 5.01 | Effects of hydroxychloroquine on the human placenta-Findings from in vitro experimental data and a systematic review. ( Baker, BC; Greenwood, SL; Hayes, DJL; Heazell, AEP; Jones, RL; Scott, RE, 2019) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 4.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 4.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "A great body of evidence suggest that hydroxychloroquine, sulfasalazine, and non-fluorinated steroids can be continued throughout pregnancy, while methotrexate and leflunomide should be discontinued 3 months before pregnancy." | 4.93 | Challenges and treatment options for rheumatoid arthritis during pregnancy. ( Gerosa, M; Meroni, PL; Schioppo, T, 2016) |
| "In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS." | 4.91 | The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. ( Alijotas-Reig, J; Andreoli, L; Benbara, A; Bertero, T; Bezanahary, H; Bremme, K; Canti, V; Carbillon, L; Dhote, R; Fain, O; Kuzenko, A; Lazzaroni, MG; Levy, P; Maurier, F; Mekinian, A; Nicaise-Roland, P; Ruffatti, A; Tigazin, A; Tincani, A, 2015) |
| " We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment." | 4.91 | Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? ( Botta, A; De Carolis, MP; De Carolis, S; Del Sordo, G; di Pasquo, E; Garufi, C; Lanzone, A; Salvi, S, 2015) |
| " Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events." | 4.90 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014) |
| " A prospective study found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus nephritis." | 4.90 | Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. ( Clowse, ME; Peart, E, 2014) |
| "The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
| "The use of Hydroxychloroquine (HCQ) during pregnancy has remained controversial for a long time." | 4.82 | [Pleading to maintain hydroxychloroquine throughout Lupus pregnancies]. ( Amoura, Z; Costedoat-Chalumeau, N; Le Thi Huong, D; Piette, JC; Wechsler, B, 2005) |
| " Recommendations were either consistent or differences were of negligible clinical relevance for: indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (±V) LN, pregnancy in LN, LN in paediatric patients and LN patients with kidney failure." | 4.31 | The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. ( Anders, HJ; Bruchfeld, A; Fernández-Juárez, GM; Floege, J; Frangou, E; Goumenos, D; Kronbichler, A; Loutan, J; Segelmark, M; Stevens, KI; Tesar, V; Turkmen, K; van Kooten, C, 2023) |
| "Hydroxychloroquine combined with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines." | 4.31 | Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. ( Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 4.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "To investigate the clinical efficacy of plasma exchange (PE) with or without prednisone and hydroxychloroquine (HCQ) for the treatment of systemic lupus erythematosus (SLE) during pregnancy." | 4.31 | Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy. ( Bu, YJ; Cao, JP; Cen, X; Chen, FW; Chen, JW; Cheng, T; Fan, R; Hu, XR; Liu, YQ; Zhang, BY; Zhang, F, 2023) |
| "Findings from previous small studies have been reassuring regarding the safety of treatment with hydroxychloroquine (HCQ) during pregnancy." | 4.12 | Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study. ( Adam, MP; Braddock, SR; Burke, L; Chambers, CD; Felix, R; Fine, M; Johnson, DL; Jones, KL; Lessard, C; Luo, Y; Robinson, LK; Xu, R, 2022) |
| "Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE." | 4.12 | Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Gonzalez, D; Hornik, CP; Maharaj, AR; Weiner, D, 2022) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 4.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| " Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy." | 4.12 | Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro. ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| " The treatment of prednisone plus HCQ may improve implantation rate, biochemical pregnancy rate, and clinical pregnancy rate, and reduce pregnancy loss rate in frozen embryo transfer outcomes for ANA-positive women." | 4.02 | Combined treatment of prednisone and hydroxychloroquine may improve outcomes of frozen embryo transfer in antinuclear antibody-positive patients undergoing IVF/ICSI treatment. ( Cheng, K; Deng, W; Gao, R; Meng, C; Qin, L; Zeng, X, 2021) |
| "Hydroxychloroquine is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity." | 4.02 | Hydroxychloroquine early in pregnancy and risk of birth defects. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Straub, L; Zhu, Y, 2021) |
| "Among pregnancies exposed to 4-aminoquinolines (chloroquine and HCQ), no increased risk of major birth defects, preterm birth, or SGA was identified." | 4.02 | Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. ( Andersen, JT; Andersson, NW; Skov, L, 2021) |
| "Hydroxychloroquine is a treatment for rheumatic disease and considered safe during pregnancy." | 4.02 | Maternal exposure to hydroxychloroquine and birth defects. ( Ailes, EC; Broussard, CS; Browne, ML; Carmichael, SL; Fisher, SC; Heinke, D; Howley, MM; Mitchell, AA; Pruitt, SM; Reefhuis, J; Van Zutphen, AR; Werler, MM, 2021) |
| "Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS." | 4.02 | The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. ( Alvarez, R; Balparda, J; Beruti, E; Fernandez Suarez, C; Gerde, M; Heer, C; Ibarra, E; Iglesias, M; Mac Kenzie, R; Rubinstein, F, 2021) |
| " Several management options for prolongation of pregnancy such as plasma exchange, pravastatin, LMHW, hydroxychloroquine/HCQ, or TNF-alpha blocker should be discussed with the patients." | 3.96 | Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. ( Cervar-Zivkovic, M; Mayer-Pickel, K; Moertl, M; Schöll, W; Stern, C, 2020) |
| " To determine pregnancy outcomes in women with systemic lupus erythematosus (SLE) who were treated with hydroxychloroquine in a tertiary center." | 3.96 | New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre. ( Abd Rahman, R; Kamisan Atan, I; Min Tun, K; Mohamed Said, MS; Mustafar, R; Zainuddin, AA, 2020) |
| " Hydroxychloroquine (HCQ) reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure." | 3.91 | Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 3.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Secondly, we estimated the prevalence of AVB among mothers with anti-Ro/La antibodies and examined the relationship of those fetal AVB with mother's use of hydroxychloroquine during pregnancy." | 3.91 | Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. ( Catoggio, LJ; Mollerach, FB; Rosa, J; Scolnik, M; Soriano, ER, 2019) |
| "This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy." | 3.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| "Steroids and hydroxychloroquine remain the most widely prescribed treatment options in pregnancy, but the use of biologic agents is becoming increasingly common." | 3.83 | Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. ( Bateman, BT; Desai, RJ; Gopalakrishnan, C; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Patorno, E, 2016) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 3.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "To describe two patients that had induction and exacerbation of psoriasis due to the administration of hydroxychloroquine, to adapt pertinent literature on the pathophysiology of this side effect, to review psoriasis-triggered cases by newer, non-quinolinic antimalarials, and to propose malaria treatment and prophylaxis guidelines for psoriatic patients." | 3.80 | Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? ( Bassukas, ID; Gaitanis, G; Gravani, A; Zioga, A, 2014) |
| "To evaluate pregnancy safety of hydroxychloroquine (HCQ) for rheumatologic diseases." | 3.79 | Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. ( Blyakhman, S; Diav-Citrin, O; Ornoy, A; Shechtman, S, 2013) |
| " Maternal treatment with either hydroxychloroquine or daily low-dose prednisone throughout pregnancy may provide a protective effect." | 3.79 | Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. ( Barker, PC; Brancazio, LR; Clowse, ME; Miller, SG; Tunks, RD, 2013) |
| " Chloroquine or hydroxychloroquine are considered safe to use in all trimesters of pregnancy." | 3.77 | Prophylactic use of antimalarials during pregnancy. ( Bozzo, P; Einarson, A; Irvine, MH, 2011) |
| " A 33-year-old G1 P0 with Cogan's syndrome experienced an uneventful pregnancy while being treated with hydroxychloroquine and prednisone." | 3.75 | Cogan's syndrome complicating pregnancy. ( Blackstone, J; Cartin, A; Currie, C; Pinette, MG; Wax, JR, 2009) |
| "Hydroxychloroquine therapy during pregnancy is thought to be safe for foetuses." | 3.75 | Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. ( Flores-Guevara, R; Gold, F; Renaud, C; Renault, F; Richard, P; Vermersch, AI, 2009) |
| "To determine the effect of hydroxychloroquine treatment during pregnancy and lactation on babies of mothers affected by rheumatic diseases." | 3.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| " hydroxychloroquine and/or prednisone) were continued during pregnancy." | 3.73 | [Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases]. ( Costedoat-Chalumeau, N; de Montgolfier, I; Gold, F; Lapillonne, A; Renaud, C; Vautier-Brouzes, D, 2006) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 3.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ)." | 3.69 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. ( Buchanan, NM; Hughes, GR; Kerslake, S; Khamashta, MA; Lima, F; Toubi, E, 1996) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 3.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies." | 3.01 | Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. ( Bacal, V; Bedaiwy, MA; Hooper, A, 2023) |
| "Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy." | 2.90 | Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. ( Bohec, C; Bretelle, F; Chauleur, C; Cogulet, V; de Saint-Martin, L; Hannigsberg, J; Lejeune-Saada, V; Marhic, G; Merviel, P; Mottier, D; Pasquier, E; Plu-Bureau, G, 2019) |
| "Pregnancy was formerly discouraged in patients with SLE because of unstable disease activity during the gestation period, increased thrombosis risk, severe organ damage, and inevitable side effects of immunosuppressive agents." | 2.82 | Pregnancy-related complications in systemic lupus erythematosus. ( Cui, L; Li, Z; Liu, Q; Mu, R; Qiao, J; Tan, Y; Yang, S, 2022) |
| " Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses." | 2.72 | Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. ( Bhagat, R; Manchanda, K; Singh, H; Singh, J; Tiwana, IK, 2021) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 2.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH." | 2.55 | Hydroxychloroquine in systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2017) |
| "Management of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively." | 2.53 | Current status and future prospects for the treatment of antiphospholipid syndrome. ( Al Marzooqi, A; Al Saleh, J; Khamashta, M; Leone, A, 2016) |
| "Congenital atrioventricular block is associated with a relatively high fetal morbidity and mortality, particularly more advanced degrees of block." | 2.52 | Controversies in the Management of Isolated Congenital Atrioventricular Block. ( DeNoble, AE; Kuller, JA; Rhee, EJ, 2015) |
| "Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit." | 2.47 | Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011) |
| " Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy." | 2.47 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. ( Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011) |
| " Although these agents have largely revolutionized the treatment of the systemic autoimmune diseases, adverse reactions, which can be serious and life threatening, to the various immunosuppressive agents used in the treatment of CTD can occur." | 2.46 | Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. ( Baughman, R; Decker, C; Meyer, KC, 2010) |
| "In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome." | 2.44 | [Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008) |
| "Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities." | 1.91 | Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. ( Craigo, S; Kuller, JA; Norton, ME; Osmundson, SS; Porter, F; Silver, R, 2023) |
| " HCQ is generally safe and may be prescribed to pregnant women." | 1.91 | Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Kaneko, K; Murashima, A; Sago, H; Tanaka, R; Tsurane, K; Yoshida, K, 2023) |
| "HCQ is safe for IgAN treatment during pregnancy with effective reduction of proteinuria." | 1.72 | The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Si, FL; Tang, C; Yao, YX; Zhang, H, 2022) |
| "To investigate the risk of gestational diabetes mellitus (GDM) associated with systemic lupus erythematosus (SLE) by comparing pregnancies in women with SLE to general population controls." | 1.72 | Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus. ( Arkema, EV; Gernaat, SAM; Simard, JF; Svenungsson, E; Wikström, AK, 2022) |
| "Catastrophic antiphospholipid antibody syndrome (CAPS) is an accelerated form of disease with rapid involvement of multiple organ systems often posing a diagnostic challenge." | 1.72 | Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean. ( Asturkar, V; Bhanu, K; Dorji, T; Hegde, A; Yangzom, S, 2022) |
| "Hydroxychloroquine (HCQ) was originally used as an anti-malaria drug and has now shown benefit in refractory OAPS where conventional treatment has failed, with the expectation of providing protective clinical benefits for both the mother and foetus." | 1.72 | Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. ( Hu, M; Liu, J; Song, S; Tian, Y; Wan, S; Wang, X; Xia, Y; Zhang, L; Zhang, M; Zhou, Q, 2022) |
| "COVID-19 and preeclampsia (preE) share the ANG-II mediated endothelial dysfunction, resulting from a significant dysregulation of RAS and an imbalanced proportion of anti-angiogenic and pro-angiogenic soluble plasmatic factors." | 1.72 | Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection. ( Acampora, E; Arienti, F; Carrer, A; Casati, M; Gambacorti-Passerini, C; Giardini, V; Ornaghi, S; Vasarri, MV; Vergani, P, 2022) |
| "Lupus nephritis was present in 20." | 1.62 | Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal. ( Barros, T; Braga, A; Braga, J; Carvalheira, G; Faria, R; Farinha, F; Marinho, A; Neves, E; Rocha, G; Vasconcelos, C, 2021) |
| "Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period." | 1.62 | A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report. ( Afrooz, N; Aminimoghaddam, S; Mahmoudzadeh, F; Motaghi Nejad, O; Nasiri, S, 2021) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 1.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "Few cases of systemic lupus erythematosus (SLE) pregnancy complicated by PA have been reported, and the background pathophysiology remains elusive." | 1.56 | Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine. ( Hiramitsu, S; Ishikawa, T; Iwahara, Y; Mano, C; Miyasaka, N; Saito, K; Sekiguchi, M; Tatsumi, T, 2020) |
| "Novel coronavirus disease 2019 is rapidly spreading throughout the New York metropolitan area since its first reported case on March 1, 2020." | 1.56 | Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. ( Andrikopoulou, M; Aubey, J; Baptiste, C; Bernstein, K; Breslin, N; D'Alton, ME; Friedman, AM; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Landau, R; Martinez, R; Miller, R; Moroz, L; Mourad, M; Purisch, S; Ring, L; Rupley, D; Sheen, JJ; Simpson, LL; Sutton, D; Wapner, R; Zork, N, 2020) |
| "The worldwide incidence of coronavirus disease 2019 (COVID-19) infection is rapidly increasing, but there exists limited information on coronavirus disease 2019 in pregnancy." | 1.56 | Coronavirus disease 2019 in pregnancy: early lessons. ( Baptiste, C; Breslin, N; D'Alton, M; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Miller, R, 2020) |
| "Hydroxychloroquine use was associated with lower APOs including pre-eclampsia, prematurity and IUGR in the univariate analyses but it was no longer significant in the GEE analysis." | 1.56 | Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia. ( Maulana, SA; Mohd, R; Mustafar, R; Rahman, RA; Said, MSM; Shaharir, SS; Shahril, NS, 2020) |
| "Hydroxychloroquine was used to treat both patients; the first patient was treated with it over a period of 14 days before showing signs of improvement." | 1.56 | Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report. ( Atef-Yekta, R; Jafary, M; Lamsehchi, A; Sadeghi, K; Sagheb, S, 2020) |
| "The pregnancy is still ongoing without any visible sequelae on the foetus so far." | 1.56 | COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report. ( Calès, P; Delaroche, L; Descamps, P; Dieli-Crimi, R; Guerin, A; Lamazou, F; Letouzey, V; Octernaud, S; Oger, P; Place, V, 2020) |
| "Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares." | 1.51 | Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| "Preterm birth was defined as a birth <37 weeks gestation." | 1.48 | Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. ( Clowse, MEB; Eudy, AM; Haroun, T; James, AH; Jayasundara, M; Neil, L, 2018) |
| "Hydroxychloroquine was found to be linked to a significantly higher live birth rate with respect to the other oral treatments in the Group II patients." | 1.48 | Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Costedoat-Chalumeau, N; Cuadrado, MJ; De Carolis, S; Gerosa, M; Grandone, E; Haladyj, E; Hoxha, A; Khamashta, MA; Latino, JO; Maina, A; Marozio, L; Mayer-Pickel, K; Mekinian, A; Meroni, PL; Morel, N; Pengo, V; Ramoni, V; Reshetnyak, T; Ruffatti, A; Sciascia, S; Serrano, F; Simchen, MJ; Tenti, S; Tincani, A; Tonello, M; Udry, S, 2018) |
| "Hydroxychloroquine treatment significantly decreased (p < 0." | 1.48 | Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure. ( Ghaffari Novin, M; Ghasemnejad, T; Ghasemnejad-Berenji, H; Ghasemnejad-Berenji, M; Hajshafiha, M; Hashemi, SM; Ilkhanizadeh, B; Nazarian, H; Sadeghpour, S, 2018) |
| "Recurrent spontaneous abortion is one of the common complications in women of childbearing age during pregnancy." | 1.48 | [Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome]. ( Li, XY; Liu, XY; Zhao, JX, 2018) |
| " The HCQ group showed a trend towards lower dosage of prednisone (OR 0." | 1.46 | Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. ( de Hair, MJH; Derksen, RHWM; Fritsch-Stork, RDE; Kroese, SJ; Lely, AT; Limper, M; van Laar, JM, 2017) |
| "Hydroxychloroquine is an anti-malarial drug which, due to its anti-inflammatory and immunomodulatory effects, is widely used for the treatment of autoimmune diseases." | 1.43 | The effects of hydroxychloroquine on endothelial dysfunction. ( Gurusinghe, S; Lim, R; Mockler, JC; Murthi, P; Rahman, R; Singh, H; Wallace, EM, 2016) |
| "An autoimmune disease was present in seven (29%) cases." | 1.42 | Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| "Thus, the pregnancy was considered a high-risk pregnancy." | 1.42 | [Systemic lupus erythematosus and a medical history of deep vein thrombosis in a 27-year-old pregnant woman]. ( Puppe, V, 2015) |
| "Twenty-six out of 93 pregnancies with systemic lupus erythematosus (SLE) experienced flares during pregnancy." | 1.42 | Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study. ( Fei, Y; Hao, D; Li, Y; Liu, Y; Luo, Y; Zhang, L; Zhao, Y, 2015) |
| " And it is safe for pregnant women and fetuses." | 1.40 | [Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus]. ( Gao, Z; Hao, D; Jin, D; Liu, J; Xu, D; Zhao, Y, 2014) |
| "Systemic lupus erythematosus was diagnosed in a 34-year-old pregnant woman because of leukopenia, typical skin rash, clinical and biochemical signs of muscle involvement, and positive serology (antinuclear antibodies and anti-double-stranded DNA)." | 1.39 | Myopathy complicating lupus pregnancy. ( d'Amati, G; Framarino-dei-Malatesta, M; Gattamelata, A; Giordano, C; Piccioni, MG; Priori, R; Valesini, G, 2013) |
| "Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus." | 1.29 | The use of hydroxychloroquine in lupus pregnancy: the British experience. ( Buchanan, NM; Hughes, GR; Khamashta, MA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (4.45) | 18.7374 |
| 1990's | 11 (4.45) | 18.2507 |
| 2000's | 22 (8.91) | 29.6817 |
| 2010's | 95 (38.46) | 24.3611 |
| 2020's | 108 (43.72) | 2.80 |
| Authors | Studies |
|---|---|
| Haase, I | 2 |
| Fischer-Betz, R | 5 |
| Braga, A | 1 |
| Barros, T | 1 |
| Faria, R | 1 |
| Marinho, A | 1 |
| Carvalheira, G | 1 |
| Rocha, G | 1 |
| Farinha, F | 1 |
| Neves, E | 1 |
| Vasconcelos, C | 2 |
| Braga, J | 1 |
| Tang, C | 2 |
| Si, FL | 1 |
| Yao, YX | 1 |
| Lv, JC | 1 |
| Shi, SF | 1 |
| Chen, YQ | 1 |
| Liu, LJ | 1 |
| Zhang, H | 1 |
| Chambers, CD | 1 |
| Johnson, DL | 1 |
| Xu, R | 1 |
| Luo, Y | 2 |
| Felix, R | 1 |
| Fine, M | 1 |
| Lessard, C | 1 |
| Adam, MP | 1 |
| Braddock, SR | 1 |
| Robinson, LK | 1 |
| Burke, L | 1 |
| Jones, KL | 1 |
| Gernaat, SAM | 1 |
| Simard, JF | 3 |
| Wikström, AK | 1 |
| Svenungsson, E | 2 |
| Arkema, EV | 1 |
| Anders, HJ | 1 |
| Loutan, J | 1 |
| Bruchfeld, A | 1 |
| Fernández-Juárez, GM | 1 |
| Floege, J | 2 |
| Goumenos, D | 1 |
| Turkmen, K | 1 |
| van Kooten, C | 1 |
| Frangou, E | 1 |
| Stevens, KI | 1 |
| Kronbichler, A | 1 |
| Segelmark, M | 1 |
| Tesar, V | 2 |
| Gao, R | 1 |
| Deng, W | 1 |
| Meng, C | 1 |
| Cheng, K | 1 |
| Zeng, X | 1 |
| Qin, L | 1 |
| Anuwutnavin, S | 1 |
| Chuenchitkultavorn, V | 1 |
| Nitiyarom, R | 1 |
| Rekhawasin, T | 1 |
| Kanjanauthai, S | 1 |
| Sompagdee, N | 1 |
| Balevic, SJ | 3 |
| Weiner, D | 1 |
| Clowse, MEB | 6 |
| Eudy, AM | 6 |
| Maharaj, AR | 1 |
| Hornik, CP | 1 |
| Cohen-Wolkowiez, M | 3 |
| Gonzalez, D | 1 |
| Bermas, B | 2 |
| Costedoat-Chalumeau, N | 13 |
| Ntali, S | 1 |
| Nikolopoulos, D | 2 |
| Pantazi, L | 1 |
| Emmanouilidou, E | 1 |
| Papagoras, C | 1 |
| Fanouriakis, A | 3 |
| Dimopoulou, D | 1 |
| Kallitsakis, I | 1 |
| Boki, K | 1 |
| Dania, V | 1 |
| Sidiropoulos, PI | 1 |
| Boumpas, DT | 4 |
| Bertsias, G | 3 |
| Chang, Y | 1 |
| Di, W | 1 |
| Wu, J | 1 |
| Balevic, S | 1 |
| Sanders-Schmidler, G | 1 |
| Kosinski, A | 1 |
| Gladman, DD | 3 |
| Molad, Y | 1 |
| Nalli, C | 1 |
| Mokbel, A | 1 |
| Tincani, A | 13 |
| Urowitz, M | 1 |
| Bay, C | 1 |
| van Noord, M | 1 |
| Petri, M | 7 |
| Westhoff, WJ | 1 |
| Smith, LH | 1 |
| Wyszynski, DF | 1 |
| Hernandez-Diaz, S | 4 |
| Dorji, T | 1 |
| Hegde, A | 1 |
| Asturkar, V | 1 |
| Yangzom, S | 1 |
| Bhanu, K | 1 |
| Hoda, M | 1 |
| Scott, W | 1 |
| Sharma, K | 1 |
| Duryea, E | 1 |
| Ikemba, C | 1 |
| Reynolds, JA | 1 |
| Gayed, M | 1 |
| Khamashta, MA | 10 |
| Leone, F | 1 |
| Toescu, V | 1 |
| Bruce, IN | 1 |
| Giles, I | 1 |
| Teh, LS | 1 |
| McHugh, N | 1 |
| Akil, M | 1 |
| Edwards, CJ | 1 |
| Gordon, C | 2 |
| Liu, J | 2 |
| Zhang, L | 4 |
| Tian, Y | 2 |
| Wan, S | 1 |
| Hu, M | 1 |
| Song, S | 1 |
| Zhang, M | 2 |
| Zhou, Q | 1 |
| Xia, Y | 2 |
| Wang, X | 2 |
| Tan, Y | 1 |
| Yang, S | 2 |
| Liu, Q | 1 |
| Li, Z | 1 |
| Mu, R | 1 |
| Qiao, J | 1 |
| Cui, L | 1 |
| Moar, L | 1 |
| Simela, C | 1 |
| Nanda, S | 1 |
| Marnerides, A | 1 |
| Al-Adnani, M | 1 |
| Nelson-Piercy, C | 2 |
| Nicolaides, KH | 1 |
| Shangaris, P | 1 |
| Choi, M | 2 |
| Byun, N | 2 |
| Hwang, JR | 2 |
| Choi, YS | 1 |
| Sung, JH | 2 |
| Choi, SJ | 3 |
| Kim, JS | 2 |
| Oh, SY | 2 |
| Roh, CR | 3 |
| Silver, R | 1 |
| Craigo, S | 1 |
| Porter, F | 1 |
| Osmundson, SS | 1 |
| Kuller, JA | 2 |
| Norton, ME | 1 |
| Li, R | 1 |
| Zhang, C | 2 |
| Wang, H | 1 |
| An, Y | 1 |
| Sandercock, PAG | 1 |
| Darbyshire, J | 1 |
| DeMets, D | 1 |
| Fowler, R | 1 |
| Lalloo, DG | 1 |
| Munavvar, M | 1 |
| Staplin, N | 1 |
| Warris, A | 1 |
| Wittes, J | 1 |
| Emberson, JR | 1 |
| Hubben, A | 1 |
| McCrae, KR | 3 |
| Polkinghorne, A | 1 |
| Branley, JM | 1 |
| Giardini, V | 1 |
| Ornaghi, S | 1 |
| Gambacorti-Passerini, C | 1 |
| Casati, M | 1 |
| Carrer, A | 1 |
| Acampora, E | 1 |
| Vasarri, MV | 1 |
| Arienti, F | 1 |
| Vergani, P | 1 |
| Seok, YS | 1 |
| Cho, GJ | 1 |
| Favre, G | 3 |
| Gerbier, E | 3 |
| Maisonneuve, E | 3 |
| Pomar, L | 3 |
| Winterfeld, U | 3 |
| Lepigeon, K | 3 |
| Bloemenkamp, KWM | 3 |
| de Bruin, O | 3 |
| Hurley, E | 3 |
| Nordeng, H | 3 |
| Siiskonen, SJ | 3 |
| Sturkenboom, MCJM | 3 |
| Baud, D | 3 |
| Panchaud, A | 3 |
| Kadife, E | 3 |
| Hannan, N | 3 |
| Harper, A | 3 |
| Binder, N | 3 |
| Beard, S | 3 |
| Brownfoot, FC | 3 |
| Tsurane, K | 3 |
| Kaneko, K | 3 |
| Yoshida, K | 3 |
| Tanaka, R | 3 |
| Sago, H | 3 |
| Murashima, A | 4 |
| Phillips, J | 3 |
| Nathan, E | 3 |
| Graham, D | 3 |
| Zhang, N | 3 |
| Zhang, HX | 3 |
| Li, YW | 3 |
| Li, Y | 4 |
| Ye, S | 2 |
| Zhao, X | 2 |
| Liu, Y | 5 |
| Ma, Y | 2 |
| Wang, Y | 2 |
| Zhao, J | 2 |
| Arachchillage, DJ | 1 |
| Laffan, M | 2 |
| Pericleous, C | 1 |
| Wei, Y | 2 |
| Zhang, Y | 2 |
| Yang, H | 2 |
| Mirzaei, M | 1 |
| Amirajam, S | 1 |
| Moghimi, ES | 1 |
| Behzadi, S | 1 |
| Rohani, A | 1 |
| Zerangian, N | 1 |
| Samani, NK | 1 |
| Soudagar, S | 1 |
| Ghazanfarpour, M | 1 |
| Moini, A | 1 |
| Sepidarkish, M | 1 |
| Dehpour, AR | 1 |
| Rabiei, M | 1 |
| Abiri, A | 1 |
| Pirjani, R | 1 |
| Lam, NV | 1 |
| Brown, JA | 1 |
| Sharma, R | 1 |
| León-Martínez, D | 1 |
| Lynn, T | 1 |
| Abrahams, VM | 2 |
| Kim, DA | 1 |
| Rho, S | 1 |
| Guo, Y | 1 |
| Su, Y | 1 |
| Ji, H | 1 |
| Zhao, C | 1 |
| Ling, X | 1 |
| Shen, R | 1 |
| Bjerkaas Hanssen, M | 1 |
| Malm Gulati, A | 1 |
| Koksvik, H | 1 |
| Wallenius, M | 1 |
| Yildirim, M | 1 |
| Oluklu, D | 1 |
| Beser, DM | 1 |
| Hendem, DU | 1 |
| Aktas, BA | 1 |
| Yildiz, EG | 1 |
| Kara, O | 1 |
| Sahin, D | 1 |
| Hooper, A | 1 |
| Bacal, V | 1 |
| Bedaiwy, MA | 1 |
| Zhang, F | 1 |
| Zhang, BY | 1 |
| Fan, R | 1 |
| Cheng, T | 1 |
| Hu, XR | 1 |
| Liu, YQ | 1 |
| Cen, X | 1 |
| Bu, YJ | 1 |
| Cao, JP | 1 |
| Chen, FW | 1 |
| Chen, JW | 1 |
| Marder, W | 1 |
| Rebić, N | 1 |
| Sayre, EC | 1 |
| Zusman, EZ | 1 |
| Amiri, N | 1 |
| Baldwin, C | 1 |
| De Vera, MA | 1 |
| de Moreuil, C | 1 |
| Alavi, Z | 1 |
| Pasquier, E | 2 |
| Do, SC | 2 |
| Rizk, NM | 1 |
| Druzin, ML | 3 |
| Mayer-Pickel, K | 2 |
| Stern, C | 1 |
| Cervar-Zivkovic, M | 1 |
| Schöll, W | 1 |
| Moertl, M | 1 |
| Parikh, SV | 1 |
| Almaani, S | 1 |
| Brodsky, S | 1 |
| Rovin, BH | 1 |
| Rahman, RA | 2 |
| Murthi, P | 3 |
| Singh, H | 3 |
| Gurungsinghe, S | 1 |
| Leaw, B | 1 |
| Mockler, JC | 2 |
| Lim, R | 2 |
| Wallace, EM | 3 |
| Saito, K | 1 |
| Mano, C | 1 |
| Tatsumi, T | 1 |
| Ishikawa, T | 1 |
| Sekiguchi, M | 1 |
| Iwahara, Y | 1 |
| Hiramitsu, S | 1 |
| Miyasaka, N | 1 |
| Doms, J | 1 |
| Horisberger, A | 1 |
| Ribi, C | 1 |
| Breslin, N | 2 |
| Baptiste, C | 2 |
| Gyamfi-Bannerman, C | 2 |
| Miller, R | 2 |
| Martinez, R | 1 |
| Bernstein, K | 1 |
| Ring, L | 1 |
| Landau, R | 1 |
| Purisch, S | 1 |
| Friedman, AM | 1 |
| Fuchs, K | 2 |
| Sutton, D | 1 |
| Andrikopoulou, M | 1 |
| Rupley, D | 1 |
| Sheen, JJ | 1 |
| Aubey, J | 1 |
| Zork, N | 1 |
| Moroz, L | 1 |
| Mourad, M | 1 |
| Wapner, R | 1 |
| Simpson, LL | 1 |
| D'Alton, ME | 1 |
| Goffman, D | 2 |
| LaCourse, S | 1 |
| John-Stewart, G | 1 |
| Adams Waldorf, KM | 1 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Pregnolato, F | 2 |
| Gerosa, M | 3 |
| Raimondo, MG | 1 |
| Comerio, C | 1 |
| Bartoli, F | 1 |
| Lonati, PA | 1 |
| Borghi, MO | 2 |
| Acaia, B | 1 |
| Ossola, MW | 1 |
| Ferrazzi, E | 1 |
| Trespidi, L | 1 |
| Meroni, PL | 6 |
| Chighizola, CB | 1 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| D'Alton, M | 1 |
| González, R | 1 |
| García-Otero, L | 1 |
| Pons-Duran, C | 1 |
| Marbán-Castro, E | 1 |
| Goncé, A | 1 |
| Llurba, E | 1 |
| Gil, MDM | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Chen, H | 1 |
| Ramírez, M | 1 |
| Bardají, A | 1 |
| Menendez, C | 1 |
| Shaharir, SS | 1 |
| Maulana, SA | 1 |
| Shahril, NS | 1 |
| Mohd, R | 1 |
| Mustafar, R | 2 |
| Said, MSM | 1 |
| Strasburger, JF | 1 |
| Wacker-Gussmann, A | 1 |
| Izmirly, P | 1 |
| Kim, M | 2 |
| Friedman, DM | 2 |
| Clancy, R | 2 |
| Copel, JA | 1 |
| Phoon, CKL | 1 |
| Cuneo, BF | 2 |
| Cohen, RE | 1 |
| Robins, K | 1 |
| Masson, M | 2 |
| Wainwright, BJ | 2 |
| Zahr, N | 2 |
| Saxena, A | 3 |
| Buyon, JP | 5 |
| Oliva, M | 1 |
| Hsu, K | 1 |
| Alsamarai, S | 1 |
| Chavez, V | 1 |
| Ferrara, L | 1 |
| Frishman, M | 1 |
| Radin, M | 2 |
| Schreiber, K | 4 |
| Janardana, R | 1 |
| Haridas, V | 1 |
| Priya, V | 1 |
| Bhat, V | 1 |
| Singh, Y | 1 |
| Rao, VK | 1 |
| Jois, R | 1 |
| Srikantiah, C | 1 |
| Pinto, B | 1 |
| Shobha, V | 1 |
| Faden, YA | 1 |
| Alghilan, NA | 1 |
| Alawami, SH | 1 |
| Alsulmi, ES | 1 |
| Alsum, HA | 1 |
| Katib, YA | 1 |
| Sabr, YS | 1 |
| Tahir, FH | 1 |
| Bondagji, NS | 1 |
| Troldborg, A | 1 |
| Bay-Laurberg, T | 1 |
| Clemmensen, K | 1 |
| Andersen, J | 1 |
| Deleuran, B | 1 |
| Carbillon, L | 5 |
| Benbara, A | 3 |
| Boujenah, J | 1 |
| Latino, JO | 3 |
| Udry, S | 3 |
| Aranda, F | 1 |
| Wingeyer, SP | 1 |
| Romero, DSF | 1 |
| Belizna, C | 2 |
| Larrañaga, G | 1 |
| Copel, J | 1 |
| Phoon, CK | 1 |
| Cohen, R | 1 |
| Izmirly, PM | 4 |
| Ni, R | 1 |
| Lu, Y | 2 |
| Wang, S | 1 |
| Xie, F | 1 |
| Lu, L | 1 |
| Sagheb, S | 1 |
| Lamsehchi, A | 1 |
| Jafary, M | 1 |
| Atef-Yekta, R | 1 |
| Sadeghi, K | 1 |
| Huybrechts, KF | 3 |
| Bateman, BT | 3 |
| Zhu, Y | 1 |
| Straub, L | 1 |
| Mogun, H | 2 |
| Kim, SC | 2 |
| Desai, RJ | 2 |
| Tziolos, N | 1 |
| Giampreti, A | 1 |
| Eleftheriou, G | 1 |
| Gallo, M | 1 |
| Butera, R | 1 |
| Contessa, G | 1 |
| Faraoni, L | 1 |
| Sangiovanni, A | 1 |
| Negri, G | 1 |
| Falchi, G | 1 |
| Bacis, G | 1 |
| Di Mascio, D | 1 |
| D'Antonio, F | 1 |
| Sadeghpour, S | 2 |
| Ghasemnejad Berenji, M | 1 |
| Nazarian, H | 2 |
| Ghasemnejad, T | 2 |
| Nematollahi, MH | 1 |
| Abroon, S | 1 |
| Paktinat, S | 1 |
| Heidari Khoei, H | 1 |
| Ghasemnejad Berenji, H | 1 |
| Ghaffari Novin, M | 2 |
| Beksac, MS | 1 |
| Donmez, HG | 1 |
| Hammad, I | 1 |
| Porter, TF | 1 |
| Knudsen, SS | 1 |
| Knudsen, JS | 1 |
| Christensen, J | 1 |
| Laursen, TM | 1 |
| Deleuran, BW | 1 |
| Bech, BH | 1 |
| Lamazou, F | 1 |
| Oger, P | 1 |
| Dieli-Crimi, R | 1 |
| Guerin, A | 1 |
| Letouzey, V | 1 |
| Octernaud, S | 1 |
| Place, V | 1 |
| Calès, P | 1 |
| Descamps, P | 1 |
| Delaroche, L | 1 |
| Andersson, NW | 1 |
| Skov, L | 1 |
| Andersen, JT | 1 |
| Abd Rahman, R | 2 |
| Min Tun, K | 1 |
| Kamisan Atan, I | 1 |
| Mohamed Said, MS | 1 |
| Zainuddin, AA | 1 |
| Khan, MSI | 1 |
| Nabeka, H | 1 |
| Akbar, SMF | 1 |
| Al Mahtab, M | 1 |
| Shimokawa, T | 1 |
| Islam, F | 1 |
| Matsuda, S | 1 |
| Manchanda, K | 1 |
| Singh, J | 1 |
| Bhagat, R | 1 |
| Tiwana, IK | 1 |
| Bermas, BL | 3 |
| Chambers, C | 1 |
| Ekobena, P | 1 |
| Ivanyuk, A | 1 |
| Livio, F | 1 |
| Ortiz Molina, E | 1 |
| Hernandez Pailos, R | 1 |
| Pola Guillen, M | 1 |
| Pascual Pedreno, A | 1 |
| Rodriguez Rodriguez, E | 1 |
| Hernandez Martinez, A | 1 |
| Dima, A | 1 |
| Jurcut, C | 1 |
| Arnaud, L | 2 |
| Sisti, G | 1 |
| Schiattarella, A | 1 |
| Sisti, A | 1 |
| Orefice, V | 1 |
| Ceccarelli, F | 1 |
| Pirone, C | 1 |
| Galoppi, P | 1 |
| Spinelli, FR | 1 |
| Alessandri, C | 1 |
| Brunelli, R | 1 |
| Perrone, G | 1 |
| Conti, F | 1 |
| Aminimoghaddam, S | 1 |
| Afrooz, N | 1 |
| Nasiri, S | 1 |
| Motaghi Nejad, O | 1 |
| Mahmoudzadeh, F | 1 |
| Xu, J | 1 |
| Chen, D | 1 |
| Yang, C | 1 |
| Peng, B | 1 |
| Dubey, P | 1 |
| Thakur, B | 1 |
| Reddy, S | 1 |
| Martinez, CA | 1 |
| Nurunnabi, M | 1 |
| Manuel, SL | 1 |
| Chheda, S | 1 |
| Bracamontes, C | 1 |
| Dwivedi, AK | 1 |
| Duan, J | 1 |
| Ma, D | 1 |
| Wen, X | 1 |
| Guo, Q | 1 |
| Gao, J | 1 |
| Zhang, G | 1 |
| Xu, K | 1 |
| Axfors, C | 1 |
| Schmitt, AM | 1 |
| Janiaud, P | 1 |
| Van't Hooft, J | 1 |
| Abd-Elsalam, S | 1 |
| Abdo, EF | 1 |
| Abella, BS | 1 |
| Akram, J | 1 |
| Amaravadi, RK | 1 |
| Angus, DC | 1 |
| Arabi, YM | 1 |
| Azhar, S | 1 |
| Baden, LR | 1 |
| Baker, AW | 1 |
| Belkhir, L | 1 |
| Benfield, T | 1 |
| Berrevoets, MAH | 1 |
| Chen, CP | 1 |
| Chen, TC | 1 |
| Cheng, SH | 1 |
| Cheng, CY | 1 |
| Chung, WS | 1 |
| Cohen, YZ | 1 |
| Cowan, LN | 1 |
| Dalgard, O | 1 |
| de Almeida E Val, FF | 1 |
| de Lacerda, MVG | 1 |
| de Melo, GC | 1 |
| Derde, L | 1 |
| Dubee, V | 1 |
| Elfakir, A | 1 |
| Gordon, AC | 1 |
| Hernandez-Cardenas, CM | 1 |
| Hills, T | 1 |
| Hoepelman, AIM | 1 |
| Huang, YW | 1 |
| Igau, B | 1 |
| Jin, R | 1 |
| Jurado-Camacho, F | 1 |
| Khan, KS | 1 |
| Kremsner, PG | 1 |
| Kreuels, B | 1 |
| Kuo, CY | 1 |
| Le, T | 1 |
| Lin, YC | 1 |
| Lin, WP | 1 |
| Lin, TH | 1 |
| Lyngbakken, MN | 1 |
| McArthur, C | 1 |
| McVerry, BJ | 1 |
| Meza-Meneses, P | 1 |
| Monteiro, WM | 1 |
| Morpeth, SC | 1 |
| Mourad, A | 1 |
| Mulligan, MJ | 1 |
| Murthy, S | 1 |
| Naggie, S | 1 |
| Narayanasamy, S | 1 |
| Nichol, A | 1 |
| Novack, LA | 1 |
| O'Brien, SM | 1 |
| Okeke, NL | 1 |
| Perez, L | 1 |
| Perez-Padilla, R | 1 |
| Perrin, L | 1 |
| Remigio-Luna, A | 1 |
| Rivera-Martinez, NE | 1 |
| Rockhold, FW | 1 |
| Rodriguez-Llamazares, S | 1 |
| Rolfe, R | 1 |
| Rosa, R | 1 |
| Røsjø, H | 1 |
| Sampaio, VS | 1 |
| Seto, TB | 1 |
| Shahzad, M | 1 |
| Soliman, S | 1 |
| Stout, JE | 1 |
| Thirion-Romero, I | 1 |
| Troxel, AB | 1 |
| Tseng, TY | 1 |
| Turner, NA | 1 |
| Ulrich, RJ | 1 |
| Walsh, SR | 1 |
| Webb, SA | 1 |
| Weehuizen, JM | 1 |
| Velinova, M | 1 |
| Wong, HL | 1 |
| Wrenn, R | 1 |
| Zampieri, FG | 1 |
| Zhong, W | 1 |
| Moher, D | 1 |
| Goodman, SN | 1 |
| Ioannidis, JPA | 1 |
| Hemkens, LG | 1 |
| Pearson, H | 1 |
| Khizroeva, J | 2 |
| Bitsadze, V | 2 |
| Makatsariya, A | 2 |
| Arslanbekova, M | 1 |
| Babaeva, N | 1 |
| Tsibizova, V | 1 |
| Shkoda, A | 1 |
| Makatsariya, N | 1 |
| Tretyakova, M | 1 |
| Solopova, A | 1 |
| Gadaeva, Z | 1 |
| Vorobev, A | 1 |
| Khamani, I | 1 |
| Aslanova, Z | 1 |
| Nakaidze, I | 1 |
| Mischenko, A | 1 |
| Grigoreva, K | 1 |
| Kunesko, N | 1 |
| Egorova, E | 1 |
| Mashkova, T | 1 |
| Chavatza, K | 1 |
| Kostopoulou, M | 1 |
| Gioti, O | 1 |
| Togia, K | 1 |
| Andreoli, L | 4 |
| Aringer, M | 2 |
| Boletis, J | 2 |
| Doria, A | 3 |
| Houssiau, FA | 2 |
| Jayne, D | 2 |
| Mosca, M | 1 |
| Dong, Y | 1 |
| Howley, MM | 1 |
| Werler, MM | 1 |
| Fisher, SC | 1 |
| Van Zutphen, AR | 1 |
| Carmichael, SL | 1 |
| Broussard, CS | 1 |
| Heinke, D | 1 |
| Ailes, EC | 1 |
| Pruitt, SM | 1 |
| Reefhuis, J | 1 |
| Mitchell, AA | 1 |
| Browne, ML | 1 |
| Gerde, M | 1 |
| Ibarra, E | 1 |
| Mac Kenzie, R | 1 |
| Fernandez Suarez, C | 1 |
| Heer, C | 1 |
| Alvarez, R | 1 |
| Iglesias, M | 1 |
| Balparda, J | 1 |
| Beruti, E | 1 |
| Rubinstein, F | 1 |
| Arachchillage, DRJ | 1 |
| Lateef, A | 1 |
| Gan, SP | 1 |
| Ong, SG | 1 |
| Lisney, AR | 1 |
| Szelinski, F | 1 |
| Reiter, K | 1 |
| Burmester, GR | 1 |
| Rose, T | 1 |
| Dörner, T | 2 |
| Yokogawa, N | 1 |
| Sumitomo, N | 1 |
| Miura, M | 1 |
| Shibuya, K | 1 |
| Nagai, H | 1 |
| Goto, M | 1 |
| Breen, K | 1 |
| Cohen, H | 1 |
| Jacobsen, S | 1 |
| Middeldorp, S | 2 |
| Pavord, S | 2 |
| Regan, L | 1 |
| Roccatello, D | 3 |
| Robinson, SE | 1 |
| Sciascia, S | 5 |
| Seed, PT | 1 |
| Watkins, L | 1 |
| Hunt, BJ | 4 |
| Cao, B | 2 |
| Parnell, LA | 1 |
| Diamond, MS | 1 |
| Mysorekar, IU | 2 |
| Jayasundara, M | 1 |
| Haroun, T | 1 |
| Neil, L | 1 |
| James, AH | 1 |
| Soh, MC | 1 |
| Westgren, M | 1 |
| McCowan, L | 1 |
| Pasupathy, D | 1 |
| Chaturvedi, S | 2 |
| De Carolis, S | 4 |
| Rizzo, F | 1 |
| Tabacco, S | 1 |
| Sheth, MN | 1 |
| Kroese, SJ | 1 |
| de Hair, MJH | 1 |
| Limper, M | 2 |
| Lely, AT | 1 |
| van Laar, JM | 1 |
| Derksen, RHWM | 1 |
| Fritsch-Stork, RDE | 1 |
| Cheloufi, M | 1 |
| Wackenheim, C | 1 |
| Dumestre-Pérard, C | 1 |
| Gueniffey, A | 1 |
| Equy, V | 1 |
| Thong-Vanh, C | 1 |
| Dunand-Faure, C | 1 |
| Hoffmann, P | 1 |
| Deroux, A | 1 |
| Siega-Riz, AM | 1 |
| Engel, SM | 1 |
| Franceschini, N | 1 |
| Howard, AG | 1 |
| Colla, L | 1 |
| Diena, D | 1 |
| Rossetti, M | 1 |
| Manzione, AM | 1 |
| Marozio, L | 2 |
| Benedetto, C | 1 |
| Biancone, L | 1 |
| Ruffatti, A | 6 |
| Tonello, M | 1 |
| Hoxha, A | 1 |
| Cuadrado, MJ | 2 |
| Reshetnyak, T | 1 |
| Morel, N | 2 |
| Haladyj, E | 1 |
| Alijotas-Reig, J | 4 |
| Tenti, S | 1 |
| Simchen, MJ | 1 |
| Bertero, MT | 2 |
| Ramoni, V | 1 |
| Mekinian, A | 5 |
| Grandone, E | 1 |
| Maina, A | 1 |
| Serrano, F | 1 |
| Pengo, V | 1 |
| Guillotin, V | 1 |
| Bouhet, A | 1 |
| Barnetche, T | 1 |
| Richez, C | 1 |
| Truchetet, ME | 1 |
| Seneschal, J | 1 |
| Duffau, P | 1 |
| Lazaro, E | 3 |
| Keeling, SO | 1 |
| Bissonauth, A | 1 |
| Bernatsky, S | 1 |
| Vandermeer, B | 1 |
| Fortin, PR | 1 |
| Peschken, C | 1 |
| Urowitz, MB | 2 |
| Green, TP | 2 |
| Schanberg, LE | 2 |
| Ghasemnejad-Berenji, H | 1 |
| Hajshafiha, M | 1 |
| Hashemi, SM | 1 |
| Ilkhanizadeh, B | 1 |
| Ghasemnejad-Berenji, M | 1 |
| Barsalou, J | 1 |
| Berhanu, A | 1 |
| Fors-Nieves, C | 1 |
| Shah, U | 1 |
| Brown, P | 1 |
| Laskin, CA | 1 |
| Levesque, K | 1 |
| Silverman, ED | 1 |
| Abad, S | 1 |
| Amital, H | 1 |
| Amoura, Z | 6 |
| Andres, E | 1 |
| Aouba, A | 1 |
| Apras Bilgen, S | 1 |
| Bienvenu, B | 1 |
| Blanco, P | 2 |
| Blank, M | 1 |
| Caligaro, A | 1 |
| Candrea, E | 1 |
| Canti, V | 2 |
| Chiche, L | 1 |
| Chretien, JM | 1 |
| Cohen Tervaert, JW | 1 |
| Damian, L | 1 |
| Delross, T | 1 |
| Dernis, E | 1 |
| Devreese, K | 1 |
| Djokovic, A | 1 |
| Esteve-Valverde, E | 1 |
| Favaro, M | 1 |
| Fassot, C | 1 |
| Ferrer-Oliveras, R | 1 |
| Godon, A | 1 |
| Hamidou, M | 1 |
| Hasan, M | 1 |
| Henrion, D | 1 |
| Imbert, B | 1 |
| Jeandel, PY | 1 |
| Jeannin, P | 1 |
| Jego, P | 1 |
| Jourde-Chiche, N | 1 |
| Lambotte, O | 1 |
| Landron, C | 1 |
| de Leeuw, K | 1 |
| Le Gallou, T | 1 |
| Kiliç, L | 1 |
| Loufrani, L | 1 |
| Lubin, R | 1 |
| Magy-Bertrand, N | 1 |
| Mahe, G | 1 |
| Martin, T | 1 |
| Muchardt, C | 1 |
| Nagy, G | 1 |
| Omarjee, L | 1 |
| Van Paasen, P | 1 |
| Pernod, G | 1 |
| Perrinet, F | 1 |
| Pïres Rosa, G | 1 |
| Pistorius, MA | 1 |
| Said, F | 1 |
| Saulnier, P | 1 |
| Sene, D | 1 |
| Sentilhes, L | 1 |
| Shovman, O | 1 |
| Sibilia, J | 1 |
| Sinescu, C | 1 |
| Stanisavljevic, N | 1 |
| Stojanovich, L | 1 |
| Tam, LS | 1 |
| Tollis, F | 1 |
| Ungeheuer, MN | 1 |
| Versini, M | 1 |
| Cervera, R | 3 |
| Kemp, M | 1 |
| Thomas, W | 1 |
| Placais, L | 1 |
| Carrat, F | 1 |
| Nicaise Roland, P | 1 |
| Cacciatore, C | 1 |
| Fain, O | 4 |
| Li, XY | 1 |
| Zhao, JX | 1 |
| Liu, XY | 1 |
| de Saint-Martin, L | 1 |
| Marhic, G | 1 |
| Chauleur, C | 1 |
| Bohec, C | 1 |
| Bretelle, F | 1 |
| Lejeune-Saada, V | 1 |
| Hannigsberg, J | 1 |
| Plu-Bureau, G | 1 |
| Cogulet, V | 1 |
| Merviel, P | 1 |
| Mottier, D | 1 |
| Chehab, G | 1 |
| Krüssel, J | 1 |
| Fehm, T | 1 |
| Schneider, M | 2 |
| Germeyer, A | 1 |
| Suerdieck, MB | 1 |
| Kreuzer, V | 1 |
| Liebenthron, J | 1 |
| Seo, MR | 1 |
| Chae, J | 1 |
| Kim, YM | 1 |
| Cha, HS | 1 |
| Oh, S | 1 |
| Mollerach, FB | 1 |
| Scolnik, M | 1 |
| Catoggio, LJ | 1 |
| Rosa, J | 1 |
| Soriano, ER | 1 |
| Scott, RE | 1 |
| Greenwood, SL | 1 |
| Hayes, DJL | 1 |
| Baker, BC | 1 |
| Jones, RL | 1 |
| Heazell, AEP | 1 |
| Priori, R | 1 |
| Gattamelata, A | 1 |
| d'Amati, G | 1 |
| Giordano, C | 1 |
| Piccioni, MG | 1 |
| Valesini, G | 1 |
| Framarino-dei-Malatesta, M | 1 |
| Diav-Citrin, O | 1 |
| Blyakhman, S | 1 |
| Shechtman, S | 1 |
| Ornoy, A | 1 |
| Gravani, A | 1 |
| Gaitanis, G | 1 |
| Zioga, A | 1 |
| Bassukas, ID | 1 |
| Albert, CR | 1 |
| Schlesinger, WJ | 1 |
| Viall, CA | 1 |
| Mulla, MJ | 1 |
| Brosens, JJ | 1 |
| Chamley, LW | 1 |
| de Jesús, GR | 1 |
| Rodrigues, G | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 3 |
| Peart, E | 1 |
| Clowse, ME | 4 |
| Cooper, WO | 1 |
| Cheetham, TC | 1 |
| Li, DK | 1 |
| Stein, CM | 1 |
| Callahan, ST | 1 |
| Morgan, TM | 1 |
| Shintani, AK | 1 |
| Chen, N | 1 |
| Griffin, MR | 1 |
| Ray, WA | 1 |
| Mar, N | 1 |
| Kosowicz, R | 1 |
| Hook, K | 1 |
| Marchetti, T | 1 |
| Wuillemin, C | 1 |
| de Moerloose, P | 1 |
| Cohen, M | 1 |
| Gupta, R | 1 |
| High, WA | 1 |
| Butler, D | 1 |
| Murase, JE | 1 |
| Hao, D | 2 |
| Xu, D | 1 |
| Jin, D | 1 |
| Zhao, Y | 2 |
| Gao, Z | 1 |
| Masseau, A | 2 |
| Botta, A | 3 |
| Chudzinski, A | 1 |
| Theulin, A | 1 |
| Emmanuelli, V | 1 |
| Hachulla, E | 1 |
| Revaux, A | 1 |
| Nicaise, P | 1 |
| Cornelis, F | 1 |
| Subtil, D | 1 |
| Montestruc, F | 1 |
| Bucourt, M | 1 |
| Chollet-Martin, S | 1 |
| De Caroli, S | 1 |
| Ambrozic, A | 1 |
| Le Guern, V | 1 |
| Fritsch-Stork, R | 1 |
| Nicaise-Roland, P | 2 |
| Carbonne, B | 1 |
| Koh, JH | 1 |
| Ko, HS | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Park, SH | 1 |
| Lazzaroni, MG | 1 |
| Kuzenko, A | 1 |
| Levy, P | 1 |
| Bremme, K | 1 |
| Bezanahary, H | 1 |
| Bertero, T | 1 |
| Dhote, R | 1 |
| Maurier, F | 1 |
| Tigazin, A | 1 |
| Puppe, V | 1 |
| Merashli, M | 1 |
| Noureldine, MH | 1 |
| Uthman, I | 1 |
| Khamashta, M | 3 |
| Salvi, S | 1 |
| di Pasquo, E | 1 |
| Del Sordo, G | 1 |
| Garufi, C | 1 |
| Lanzone, A | 1 |
| De Carolis, MP | 1 |
| Tedeschi, SK | 2 |
| Massarotti, E | 1 |
| Guan, H | 2 |
| Fine, A | 2 |
| Costenbader, KH | 2 |
| Leroux, M | 1 |
| Desveaux, C | 1 |
| Parcevaux, M | 1 |
| Julliac, B | 1 |
| Gouyon, JB | 1 |
| Dallay, D | 1 |
| Pellegrin, JL | 1 |
| Boukerrou, M | 1 |
| DeNoble, AE | 1 |
| Rhee, EJ | 1 |
| Fei, Y | 1 |
| Branch, DW | 1 |
| Ruiz-Irastorza, G | 3 |
| Talavera-Garcia, E | 1 |
| Lliso, G | 1 |
| Gopalakrishnan, C | 1 |
| Patorno, E | 1 |
| Kaplan, YC | 1 |
| Ozsarfati, J | 1 |
| Nickel, C | 1 |
| Koren, G | 5 |
| Noviani, M | 1 |
| Wasserman, S | 1 |
| Al Marzooqi, A | 1 |
| Leone, A | 1 |
| Al Saleh, J | 1 |
| Bertolaccini, ML | 1 |
| Contento, G | 1 |
| Lennen, R | 1 |
| Sanna, G | 1 |
| Blower, PJ | 1 |
| Ma, MT | 1 |
| Sunassee, K | 1 |
| Girardi, G | 1 |
| Schioppo, T | 1 |
| Merino Argumánez, C | 1 |
| Sáez de La Fuente, I | 1 |
| Molina Collado, Z | 1 |
| Suárez Pita, D | 1 |
| Mestre Gómez, B | 1 |
| Sanchez Izquierdo, JA | 1 |
| Ponticelli, C | 1 |
| Moroni, G | 2 |
| Rahman, R | 1 |
| Gurusinghe, S | 1 |
| Bazzan, M | 1 |
| DeKoninck, P | 1 |
| Fleury, O | 1 |
| Droitcourt, C | 1 |
| Polard, E | 1 |
| Chevrant-Breton, J | 1 |
| Bérezné, A | 1 |
| Mouthon, L | 1 |
| Currie, C | 1 |
| Wax, JR | 1 |
| Pinette, MG | 1 |
| Blackstone, J | 1 |
| Cartin, A | 1 |
| Renault, F | 1 |
| Flores-Guevara, R | 1 |
| Renaud, C | 2 |
| Richard, P | 1 |
| Vermersch, AI | 1 |
| Gold, F | 2 |
| Ingster-Moati, I | 1 |
| Albuisson, E | 1 |
| Iba-Ba, J | 1 |
| Mayi-Tsonga, S | 1 |
| Ibouili Bignoumba, R | 1 |
| Diallo, T | 1 |
| Moussavou Kombila, JB | 1 |
| Coniquet, S | 1 |
| Mihindou Boussougou, C | 1 |
| Boguikouma, JB | 1 |
| Pisoni, CN | 2 |
| Brucato, A | 2 |
| Espinosa, G | 1 |
| Belmonte-Serrano, M | 1 |
| Sánchez-Román, J | 1 |
| García-Hernández, FG | 1 |
| Hughes, GR | 5 |
| Teh, CL | 1 |
| Wong, JS | 1 |
| Ngeh, NK | 1 |
| Loh, WL | 1 |
| Kim, MY | 2 |
| Llanos, C | 2 |
| Le, PU | 1 |
| Guerra, MM | 1 |
| Askanase, AD | 1 |
| Salmon, JE | 1 |
| Meyer, KC | 1 |
| Decker, C | 1 |
| Baughman, R | 1 |
| Partlett, R | 1 |
| Roussou, E | 1 |
| Abarientos, C | 1 |
| Sperber, K | 1 |
| Shapiro, DL | 1 |
| Aronow, WS | 1 |
| Chao, CP | 1 |
| Ash, JY | 1 |
| Scoble, T | 1 |
| Wijetilleka, S | 1 |
| Mulholland, CP | 1 |
| Pollock, TJ | 1 |
| Esposito, F | 1 |
| Galfetti, M | 1 |
| Lava, SA | 1 |
| Balestra, B | 1 |
| Bianchetti, MG | 1 |
| Wu, XX | 1 |
| Guller, S | 1 |
| Rand, JH | 1 |
| Osadchy, A | 1 |
| Ratnapalan, T | 1 |
| Irvine, MH | 1 |
| Einarson, A | 1 |
| Bozzo, P | 1 |
| Ma, L | 1 |
| Lin, B | 1 |
| Wu, DH | 1 |
| Wang, GC | 1 |
| Friedman, D | 1 |
| Piette, JC | 5 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Bertsias, GK | 1 |
| Tektonidou, M | 1 |
| Bajema, I | 1 |
| Berden, JH | 1 |
| Ferrario, F | 1 |
| Ioannidis, JP | 1 |
| Isenberg, DA | 1 |
| Kallenberg, CG | 1 |
| Lightstone, L | 1 |
| Marks, SD | 1 |
| Martini, A | 1 |
| Neumann, I | 1 |
| Praga, M | 1 |
| Starra, A | 1 |
| van Vollenhoven, RF | 1 |
| Zakharova, H | 1 |
| Haubitz, M | 1 |
| Tunks, RD | 1 |
| Miller, SG | 1 |
| Brancazio, LR | 1 |
| Barker, PC | 1 |
| Langen, ES | 1 |
| Chakravarty, EF | 1 |
| Liaquat, M | 1 |
| El-Sayed, YY | 1 |
| Nasonov, EL | 1 |
| Harten, P | 1 |
| Duhaut, P | 1 |
| Huong, DL | 2 |
| Sebbough, D | 1 |
| Wechsler, B | 3 |
| Vauthier, D | 2 |
| Denjoy, I | 1 |
| Lupoglazoff, JM | 1 |
| Cimaz, R | 2 |
| Meregalli, E | 2 |
| Biggioggero, M | 1 |
| Borghi, O | 1 |
| Motta, M | 4 |
| Airò, P | 1 |
| Muscará, M | 1 |
| Sergi, P | 1 |
| Faden, D | 2 |
| Zinzini, E | 2 |
| Lojacono, A | 2 |
| Marchesi, A | 1 |
| Frassi, M | 1 |
| Biasini, C | 1 |
| Zatti, S | 1 |
| Chirico, G | 3 |
| Lechat, P | 1 |
| Le Thi Huong, D | 1 |
| de Montgolfier, I | 1 |
| Vautier-Brouzes, D | 1 |
| Lapillonne, A | 1 |
| Magder, L | 1 |
| Witter, F | 1 |
| Golding, A | 1 |
| Haque, UJ | 1 |
| Giles, JT | 1 |
| Ciardelli, L | 1 |
| Marconi, M | 1 |
| Gasparoni, A | 1 |
| Lanham, JG | 1 |
| Suhonen, R | 1 |
| Tanenbaum, L | 1 |
| Tuffanelli, DL | 1 |
| Nashel, DJ | 1 |
| Ulmer, CC | 1 |
| Wallace, DJ | 1 |
| Lima, F | 2 |
| Alves, J | 1 |
| Simpson, J | 1 |
| Buchanan, NM | 3 |
| Toubi, E | 1 |
| Kerslake, S | 1 |
| Parke, AL | 2 |
| Rothfield, NF | 1 |
| Parke, A | 1 |
| West, B | 1 |
| Rynes, RI | 1 |
| Hollister, JR | 1 |
| Vilela, VS | 1 |
| Cataldo, MJ | 1 |
| Ramos, RC | 1 |
| Duarte, JL | 1 |
| Tura, BR | 1 |
| Albuquerque, EM | 1 |
| Jesús, NR | 1 |
| Klinger, G | 1 |
| Morad, Y | 1 |
| Westall, CA | 1 |
| Laskin, C | 1 |
| Spitzer, KA | 1 |
| Ito, S | 1 |
| Buncic, RJ | 1 |
| Aymard, G | 1 |
| Le, TH | 1 |
| Dermer, ME | 1 |
| Darbois, Y | 1 |
| Milazzo, S | 1 |
| Howard, D | 1 |
| Repke, J | 1 |
| Levy, M | 1 |
| Buskila, D | 1 |
| Greenberg, AE | 1 |
| Kloser, P | 1 |
| Deloron, P | 1 |
| Williams, SB | 1 |
| Korzhova, VV | 1 |
| Aleksandrova, SS | 1 |
| Lisitsyna, NT | 1 |
| Ostensen, M | 1 |
| Brown, ND | 1 |
| Chiang, PK | 1 |
| Aarbakke, J | 1 |
| Schmidt, H | 1 |
| Snitker, G | 1 |
| Thomsen, K | 1 |
| Lintrup, J | 1 |
| Ross, JB | 1 |
| Garatsos, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen: A Randomized Study[NCT05207358] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | ||
| A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men[NCT04365127] | Phase 1 | 40 participants (Actual) | Interventional | 2020-04-27 | Completed | ||
| Valuation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19[NCT04598347] | 225 participants (Anticipated) | Observational [Patient Registry] | 2020-08-08 | Recruiting | |||
| Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum[NCT04410562] | Phase 3 | 129 participants (Actual) | Interventional | 2020-05-13 | Completed | ||
| Preventive Approach to Congenital Heart Block With Hydroxychloroquine[NCT01379573] | Phase 2 | 74 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328] | Phase 3 | 336 participants (Anticipated) | Interventional | 2020-05-19 | Not yet recruiting | ||
| "Constitution d'Une Cohorte Prospective de Sujets Sains et Malades et d'Une Collection de Ressources Biologiques associées Pour l'étude du système Immunitaire et de Ses déterminants Génétiques et Environnementaux"[NCT03925272] | 2,200 participants (Anticipated) | Interventional | 2011-02-02 | Recruiting | |||
| Collection d'échantillons Biologiques Humains de Sujets Sains et Malades Pour la Mise au Point et la Validation de Nouvelles méthodes de Diagnostic et Pour la réalisation d'Expertises Dans le Domaine Des Maladies Infectieuses et Tropicales[NCT03912246] | 800 participants (Actual) | Interventional | 2009-04-27 | Completed | |||
| Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo[NCT03165136] | Phase 3 | 300 participants (Anticipated) | Interventional | 2017-12-04 | Active, not recruiting | ||
| A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269] | Phase 4 | 384 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome[NCT04275778] | Phase 2 | 110 participants (Anticipated) | Interventional | 2021-07-09 | Recruiting | ||
| Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis[NCT05247554] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| Home Monitoring of Fetal Heart Rhythm in Pregnancies of Anti-Ro/SSA Positive Women for the Treatment of Congenital Heart Block (FETAL HOPE)[NCT05958446] | 200 participants (Anticipated) | Observational | 2022-04-14 | Recruiting | |||
| Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis[NCT04146220] | Phase 4 | 32 participants (Actual) | Interventional | 2018-07-16 | Completed | ||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01379573)
Timeframe: At birth (approximately 9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
a) shortening fraction <28% = 2 SD below normal mean or qualitatively reduced systolic function; b) cardio-thoracic ratio >0.33; c) hydropic changes; d) moderate/severe tricuspid regurgitation. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
(NCT01379573)
Timeframe: At birth (approximately 9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 1 |
(NCT01379573)
Timeframe: Up to 15 months (at birth - 9 months, and 6 months thereafter)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 4 |
(see title) (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
"An autopsy with full evaluation of the heart will be encouraged but cannot be mandated. If AV block or evidence of a cardiomyopathy can be proven, then these will provide the basis for final categorization. If not possible, the death will not be considered a recurrence rate but will be reported." (NCT01379573)
Timeframe: Up to 9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
(gestational age <37 weeks at birth) (NCT01379573)
Timeframe: At birth (approximately 9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 9 |
EKG at birth must confirm 1st degree AV block. It is also possible that a fetus developing 1st degree block on study medication might have developed more advanced block in the absence of study medication. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
Echocardiogram reveals 2nd or 3rd degree AV block (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 5 |
77 reviews available for hydroxychloroquine and Pregnancy
| Article | Year |
|---|---|
[State of the art: fertility and pregnancy in rheumatic diseases].
Topics: Female; Fertility; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy C | 2021 |
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Pregnancy-related complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Systemic; Pregnancy; Pregn | 2022 |
Chronic histiocytic intervillositis (CHI): current treatments and perinatal outcomes, a systematic review and a meta-analysis.
Topics: Abortion, Spontaneous; Adalimumab; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxych | 2022 |
Emerging Therapies in Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydroxychlo | 2022 |
Medications for early treatment of COVID-19 in Australia.
Topics: Antibodies, Monoclonal; Antibodies, Viral; Antiviral Agents; COVID-19 Drug Treatment; Female; Humans | 2022 |
Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome.
Topics: Anticoagulants; Antimalarials; Antiphospholipid Syndrome; Female; Fibrinolytic Agents; Humans; Hydro | 2023 |
Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis.
Topics: Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; Hypertension, Pregnan | 2023 |
The effects of hydroxychloroquine on pregnancy outcomes in infertile women: a systematic review and meta-analysis.
Topics: Female; Humans; Hydroxychloroquine; Infertility, Female; Live Birth; Prednisone; Pregnancy; Pregnanc | 2023 |
Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Birth Rate; | 2023 |
Update on pregnancy complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Complication | 2019 |
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.
Topics: Abortion, Habitual; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2020 |
Pregnancy and Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newborn | 2020 |
Update on Lupus Nephritis: Core Curriculum 2020.
Topics: Adaptive Immunity; Adrenal Cortex Hormones; Age Distribution; Autoantibodies; Autoimmunity; Biopsy; | 2020 |
[Pregnancy with lupus erythematosus-an update].
Topics: Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregna | 2020 |
[Management of the antiphospholipid syndrome in adults].
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydr | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Case-Control Studies; Female; Humans; Hydro | 2020 |
[Hydroxychloroquine treatment rarely causes eye damage when used correctly].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Lupus Erythematosus | 2020 |
Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani | 2020 |
Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.
Topics: Anti-Infective Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drugs, Investigational; | 2021 |
[Pharmacovigilance update].
Topics: Adenosine Monophosphate; Alanine; Cleft Lip; Contraindications, Drug; COVID-19 Drug Treatment; Cytok | 2021 |
Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Infant, Newborn; | 2021 |
The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: A systematic review and meta-analysis.
Topics: Adult; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Complicat | 2021 |
Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Asia; Cesarean Section; COVID-19; COVID-19 Drug Trea | 2021 |
Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Case-Control Studies; Diabetes, Gestational; Female; HE | 2021 |
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Topics: Adult; Child; Chloroquine; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Drug Treatment | 2021 |
Pathogenesis and management of antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; beta 2-Glycoprotein I; Complement Inactiv | 2017 |
Systemic Lupus Erythematosus and Pregnancy.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychlo | 2017 |
Neonatal lupus erythematosus.
Topics: Antibodies, Antinuclear; Autoantibodies; Biomarkers; Female; Humans; Hydroxychloroquine; Infant, New | 2017 |
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Topics: Adult; Antiphospholipid Syndrome; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2017 |
Diagnosis and management of the antiphospholipid syndrome.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Disease Management; En | 2017 |
Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.
Topics: Azathioprine; Biological Products; Calcineurin Inhibitors; Cyclophosphamide; Directive Counseling; F | 2018 |
Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.
Topics: Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Infant, Newborn; | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
Antiphospholipid syndrome in obstetrics.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; | 2018 |
Systemic lupus erythematosus in pregnancy: high risk, high reward.
Topics: Adult; Counseling; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Lupus Erythematosus | 2019 |
Effects of hydroxychloroquine on the human placenta-Findings from in vitro experimental data and a systematic review.
Topics: Animals; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Placenta; Pregnancy | 2019 |
[Rheumatic diseases in pregnancy].
Topics: Europe; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Practice Guidelines as Topic; | 2013 |
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda | 2014 |
Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Cohort Studies; Female; Heart Block; Humans; Hydrox | 2014 |
Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?
Topics: Anti-Inflammatory Agents; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
Antiphospholipid syndrome: an update.
Topics: Adrenal Cortex Hormones; Animals; Annexin A2; Anticoagulants; Antiphospholipid Syndrome; Drugs, Inve | 2015 |
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; | 2015 |
Controversies in the Management of Isolated Congenital Atrioventricular Block.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Atrioventricular Block; Dexamethasone; Female; Histo | 2015 |
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H | 2016 |
The antiphospholipid syndrome: still an enigma.
Topics: Administration, Oral; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta | 2015 |
Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Autoimmune Diseases; Female; Humans; Hydroxychloroquine | 2016 |
Current status and future prospects for the treatment of antiphospholipid syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; Female; Humans; Hydroxychloroqui | 2016 |
Challenges and treatment options for rheumatoid arthritis during pregnancy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Hydroxychloroquine | 2016 |
Hydroxychloroquine, a potentially lethal drug.
Topics: Adult; Anisocoria; Coma; Connective Tissue Diseases; Emergencies; Female; Heart Arrest; Humans; Hydr | 2017 |
Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnan | 2016 |
Pregnancy and Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Fetal Growth Retardation; Humans; H | 2016 |
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Topics: Animals; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pr | 2017 |
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antic | 2017 |
Treatment of preeclampsia with hydroxychloroquine: a review.
Topics: Adjuvants, Pharmaceutic; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2018 |
[Pregnancy in systemic sclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr | 2008 |
Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimetabolites; Autoimmune Diseases; Benzamides; C | 2010 |
The treatment of rheumatoid arthritis during pregnancy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; | 2011 |
Lupus and pregnancy: integrating clues from the bench and bedside.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Azathioprine; Counseli | 2011 |
Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Hydr | 2011 |
Management of refractory anti-phospholipid syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antiphospholipid Syndrome; Clinical Trials as Topic; Evidenc | 2011 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
Immunosuppressive drug use in pregnancy.
Topics: Adrenal Cortex Hormones; Azathioprine; Breast Feeding; Cyclophosphamide; Cyclosporine; Female; Fetal | 2003 |
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
Topics: Antirheumatic Agents; Breast Feeding; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 2005 |
[Pleading to maintain hydroxychloroquine throughout Lupus pregnancies].
Topics: Antirheumatic Agents; Disease Progression; Female; Humans; Hydroxychloroquine; Lactation; Lupus Eryt | 2005 |
Rheumatoid arthritis and reproduction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Immunosuppre | 2007 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Femal | 1982 |
Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Chloroquine; DNA; Eye Diseases; Female; Hemat | 1980 |
Antimalarial agents and lupus.
Topics: Antibodies, Antiphospholipid; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Kidney | 1994 |
Antimalarial drugs in pregnancy--the North American experience.
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus | 1996 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Antimalarials; Chloroquine; Contraindications; Female; Humans; Hydroxychloroquine; Male; Pregnancy; | 1997 |
Medical treatment of adolescents with rheumatic disease.
Topics: Adolescent; Adolescent Medicine; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; A | 1998 |
13 trials available for hydroxychloroquine and Pregnancy
| Article | Year |
|---|---|
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.
Topics: Adult; Child; Clinical Trials Data Monitoring Committees; COVID-19; Dexamethasone; Female; Humans; H | 2022 |
The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study "pilot study".
Topics: Abortion, Habitual; Double-Blind Method; Female; Humans; Hydroxychloroquine; Infant; Pregnancy; Preg | 2022 |
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
Topics: Administration, Oral; Adult; Autoantibodies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fe | 2020 |
Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.
Topics: Antiviral Agents; Cardiotoxicity; Drug Administration Schedule; Drug Monitoring; Electrocardiography | 2020 |
A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIv
Topics: Abortion, Habitual; COVID-19; Female; Fetus; Humans; Hydroxychloroquine; Immunosuppressive Agents; M | 2020 |
Effects of treatment with hydroxychloroquine on the modulation of Th17/Treg ratio and pregnancy outcomes in women with recurrent implantation failure: clinical trial.
Topics: Adult; CD4 Lymphocyte Count; Cytokines; Embryo Implantation; Embryo Transfer; Endometrium; Female; F | 2020 |
HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antipho
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Double-Blind Method; Enzyme Inhibito | 2017 |
Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study.
Topics: Abortion, Habitual; Administration, Oral; Double-Blind Method; Female; France; Gestational Age; Huma | 2019 |
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Topics: Antirheumatic Agents; Birth Weight; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hydr | 2003 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Topics: Antimalarials; Child, Preschool; Contraindications; Female; Fetus; Follow-Up Studies; Hearing Disord | 1996 |
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Topics: Adult; Antimalarials; Double-Blind Method; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2001 |
157 other studies available for hydroxychloroquine and Pregnancy
| Article | Year |
|---|---|
Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newbor | 2021 |
The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.
Topics: Adult; Cohort Studies; Female; Glomerulonephritis, IGA; Humans; Hydroxychloroquine; Kidney Function | 2022 |
Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study.
Topics: Abortion, Spontaneous; Cohort Studies; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; | 2022 |
Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus.
Topics: Diabetes, Gestational; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2022 |
The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021.
Topics: Biopsy; Child; Female; Glomerulonephritis, Membranous; Humans; Hydroxychloroquine; Immunosuppressive | 2023 |
Combined treatment of prednisone and hydroxychloroquine may improve outcomes of frozen embryo transfer in antinuclear antibody-positive patients undergoing IVF/ICSI treatment.
Topics: Abortion, Spontaneous; Antibodies, Antinuclear; Embryo Transfer; Female; Fertilization in Vitro; Hum | 2021 |
Prenatal predisposing factors associated with neonatal lupus erythematosus.
Topics: Antibodies, Antinuclear; Case-Control Studies; Causality; Female; Humans; Hydroxychloroquine; Infant | 2022 |
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.
Topics: Antibodies, Antiphospholipid; Azathioprine; Female; Glucocorticoids; Humans; Hydroxychloroquine; Inf | 2022 |
Systemic Lupus Erythematosus Increases the Risk of Gestational Diabetes: Truth or Illusion?
Topics: Antirheumatic Agents; Diabetes, Gestational; Female; Humans; Hydroxychloroquine; Illusions; Lupus Er | 2022 |
COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy.
Topics: COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Infant, Newborn; Pregnancy; P | 2022 |
Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.
Topics: Adult; Antiphospholipid Syndrome; Cyclophosphamide; Female; Humans; Hydroxychloroquine; Immunoglobul | 2022 |
Reversal of Fetal Heart Block in Antibody-Positive Mother After Hydroxychloroquine and Dexamethasone.
Topics: Adult; Antibodies, Antinuclear; Atrioventricular Block; Dexamethasone; Female; Fetal Heart; Humans; | 2023 |
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine.
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Child; Female; Humans; Hydroxychloroquine; Lupus Ery | 2023 |
Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine | 2022 |
Effect of hydroxychloroquine and chloroquine on syncytial differentiation and autophagy in primary human trophoblasts.
Topics: Autophagy; Cell Differentiation; Chloroquine; Female; Glypicans; Humans; Hydroxychloroquine; Pregnan | 2022 |
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Wei | 2023 |
Breastfeeding by a mother taking cyclosporine for nephrotic syndrome.
Topics: Adult; Breast Feeding; Cyclosporine; Female; Humans; Hydroxychloroquine; Infant; Mothers; Nephrotic | 2022 |
Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection.
Topics: Angiogenesis Inducing Agents; Biomarkers; COVID-19; Female; Fibrinolytic Agents; Humans; Hydroxychlo | 2022 |
Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model.
Topics: Animals; Blood Pressure; Endothelial Cells; Endothelin-1; Female; Hydroxychloroquine; Hypertension; | 2022 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Topics: Antiviral Agents; COVID-19; Female; Humans; Hydroxychloroquine; Inpatients; Pregnancy; Pregnancy Com | 2023 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
Systemic Lupus Erythematosus: Diagnosis and Treatment.
Topics: Abortion, Spontaneous; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; | 2023 |
Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine.
Topics: Aspirin; Cell Line; Cell-Free Nucleic Acids; DNA; Female; Humans; Hydroxychloroquine; Placenta; Pre- | 2023 |
Peters Anomaly in One Premature Twin Following Hydroxychloroquine Exposure During Pregnancy: A Case Report.
Topics: Anterior Eye Segment; Corneal Opacity; Eye Abnormalities; Female; Humans; Hydroxychloroquine; Pregna | 2023 |
Hydroxychloroquine improves pregnancy outcomes in patients undergoing frozen embryo transfer with positive serum autoantibodies.
Topics: Autoantibodies; Embryo Transfer; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Outcome; R | 2023 |
Breastfeeding in women with systemic lupus erythematosus: results from a Norwegian quality register.
Topics: Breast Feeding; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregna | 2023 |
The assessment of fetal cardiac functions in pregnancies with autoimmune diseases: a prospective case-control study.
Topics: Autoimmune Diseases; Case-Control Studies; Echocardiography, Doppler; Female; Fetal Heart; Humans; H | 2023 |
Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Plasma Exch | 2023 |
Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Topics: Abatacept; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirh | 2020 |
Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies?
Topics: Adult; Antirheumatic Agents; California; Female; Humans; Hydroxychloroquine; Logistic Models; Lupus | 2020 |
Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases.
Topics: Adult; Antiphospholipid Syndrome; Female; Fetal Viability; Gestational Age; Heparin, Low-Molecular-W | 2020 |
Hydroxychloroquine Mitigates the Production of 8-Isoprostane and Improves Vascular Dysfunction: Implications for Treating Preeclampsia.
Topics: Cell Hypoxia; Cell Survival; Dinoprost; Endoglin; Female; Human Umbilical Vein Endothelial Cells; Hu | 2020 |
Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine.
Topics: Adult; Blastocyst; Cesarean Section; Cryopreservation; Embryo Transfer; Female; Freezing; Humans; Hy | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Asymptomatic Diseases; Azithromycin; Carrier State; C | 2020 |
Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials.
Topics: Antiviral Agents; Betacoronavirus; Breast Feeding; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies.
Topics: Adult; Algorithms; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Aspirin; beta 2-Glycop | 2021 |
Coronavirus disease 2019 in pregnancy: early lessons.
Topics: Acute Kidney Injury; Adult; Anesthesia, General; Anti-Bacterial Agents; Antihypertensive Agents; Azi | 2020 |
Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mala | 2020 |
Congenital Heart Block in Subsequent Pregnancies of SSA/Ro-Positive Mothers: Cutting Recurrence in Half.
Topics: Antibodies, Antinuclear; Female; Fetus; Heart Block; Humans; Hydroxychloroquine; Mothers; Pregnancy | 2020 |
Clinical improvement of severe COVID-19 pneumonia in a pregnant patient after caesarean delivery.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Ceft | 2020 |
Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hydroxychloroquine; India; Infant, Newborn; Lupus Eryt | 2020 |
Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019.
Topics: Anticoagulants; Antiviral Agents; Betacoronavirus; Congenital Abnormalities; Coronavirus Infections; | 2020 |
Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.
Topics: Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pregnancy; SARS-CoV-2 | 2021 |
Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Hy | 2020 |
Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report.
Topics: Adult; Antiviral Agents; Betacoronavirus; Blood Chemical Analysis; Coronavirus Infections; COVID-19; | 2020 |
Hydroxychloroquine early in pregnancy and risk of birth defects.
Topics: Abnormalities, Drug-Induced; Adult; COVID-19; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnan | 2021 |
Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy.
Topics: Abnormalities, Drug-Induced; Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Congenital Abno | 2020 |
Perinatal mortality and morbidity of SARS-COV-2 infection during pregnancy in European countries: Findings from an international study.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Asia; Asymptomatic Infections; Austr | 2021 |
Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Immune System; Infant, Newborn; Pharmaceut | 2021 |
Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - A Danish population-based study.
Topics: Academic Performance; Adolescent; Adolescent Development; Adult; Child; Child Development; Denmark; | 2021 |
COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report.
Topics: Adult; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Diagnosis, Differ | 2020 |
Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Cohort Studies; Denmark; Female; Humans; Hydroxychlor | 2021 |
New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre.
Topics: Adult; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Malaysia; | 2020 |
Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Congenital Abnormalities; COVID-1 | 2020 |
Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Complications | 2021 |
Hydroxychloroquine early in pregnancy and risk of birth defects: don't throw out the baby with the bathwater.
Topics: Female; Humans; Hydroxychloroquine; Pregnancy | 2021 |
COVID-19 infection in symptomatic pregnant women at the midpoint of the pandemic in Spain: a retrospective analysis.
Topics: Adult; Anosmia; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; C-Reactive Protein; Cesarea | 2020 |
Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Female; H | 2020 |
Breastfeeding in women affected by systemic lupus erythematosus: Rate, duration and associated factors.
Topics: Adult; Breast Feeding; Cesarean Section; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2021 |
A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report.
Topics: Acute Kidney Injury; Amphetamine-Related Disorders; Antiviral Agents; COVID-19; Drug Combinations; E | 2021 |
How COVID broke the evidence pipeline.
Topics: Child, Preschool; Clinical Decision-Making; Clinical Trials as Topic; COVID-19; Dexamethasone; Evide | 2021 |
Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Endothelial Cells; | 2022 |
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Aspirin; Drug Tapering; Europe; Fema | 2021 |
Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Endothelial Cells; Fema | 2022 |
Maternal exposure to hydroxychloroquine and birth defects.
Topics: COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Maternal Exposure; Pregnancy; Pregnancy | 2021 |
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Cohort Studies; Female; Humans; Hydroxychloroquine; Placenta; Pregnancy; | 2021 |
Antithrombotic effects of hydroxychloroquine in a pregnant patient with Antiphospholipid syndrome and recurrent venous thromboembolism.
Topics: Antiphospholipid Syndrome; Antithrombins; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy C | 2017 |
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Che | 2017 |
Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice.
Topics: Animals; Autophagy; Female; Hydroxychloroquine; Infectious Disease Transmission, Vertical; Mice; Mic | 2017 |
Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cesarean Section; Female; Ges | 2018 |
Hydroxychloroquine as additional treatment in pregnant patients with refractory APS.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnan | 2017 |
To Zika and destroy: an antimalarial drug protects fetuses from Zika infection.
Topics: Animals; Antimalarials; Autophagy; Disease Models, Animal; Drug Repositioning; Female; Fetus; Humans | 2018 |
Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infan | 2017 |
[Use of hydroxychloroquine and prednisone in the presence of serum autoimmunity in female infertility].
Topics: Adult; Autoantibodies; Autoimmunity; Female; Humans; Hydroxychloroquine; Infertility, Female; Predni | 2018 |
Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Antirheumatic Agents; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus E | 2018 |
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.
Topics: Administration, Oral; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphosphol | 2018 |
Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.
Topics: Adult; Antimalarials; Antirheumatic Agents; Biological Products; Canada; Cardiovascular Diseases; Fe | 2018 |
Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Models, Biological; Pregnancy; Rheu | 2019 |
Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure.
Topics: Adult; Embryo Implantation; Female; Fertilization in Vitro; Humans; Hydroxychloroquine; Immunomodula | 2018 |
Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosu | 2019 |
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
Topics: Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; | 2018 |
Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study.
Topics: Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Fran | 2019 |
[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].
Topics: Abortion, Habitual; Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2018 |
Too Little of a Good Thing: Hydroxychloroquine in Pregnancy.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Pregnancy; Pregnancy Complications; Rheumatic D | 2019 |
Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Cryopreservation; Cyclophosphamide; Female; | 2019 |
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Infant, Newborn; L | 2019 |
Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies.
Topics: Adult; Antibodies, Antinuclear; Argentina; Atrioventricular Block; Autoimmune Diseases; Autoimmunity | 2019 |
Myopathy complicating lupus pregnancy.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Biopsy; Drug Therapy, Combination; Female; Hum | 2013 |
Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Birth Weight; Crohn | 2013 |
Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria?
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Infant, Newborn; Malaria; Practice Guideli | 2014 |
Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Cell Line; Cell Movem | 2014 |
Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.
Topics: Adult; Arthritis; Cohort Studies; Congenital Abnormalities; Female; Fetal Death; Follow-Up Studies; | 2014 |
Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.
Topics: Abortion, Spontaneous; Adult; Antiphospholipid Syndrome; Enzyme Inhibitors; Female; Humans; Hydroxyc | 2014 |
Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies.
Topics: Adult; Antibodies; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; beta 2-Glycoprotein I; C | 2014 |
Medicolegal aspects of prescribing dermatological medications in pregnancy.
Topics: Acne Vulgaris; Alopecia; Dermatitis, Atopic; Dermatologic Agents; Dermatology; Female; Fetal Disease | 2013 |
[Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Compl | 2014 |
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi | 2015 |
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Apgar Score; Female; Fetal Growth Retardation; Follow-Up Studies; Human | 2015 |
[Systemic lupus erythematosus and a medical history of deep vein thrombosis in a 27-year-old pregnant woman].
Topics: Adult; Antirheumatic Agents; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Hyd | 2015 |
Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Humans; Hydroxychloroquine; Logistic Models; Lupu | 2015 |
Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Gluc | 2015 |
Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Connective Tissue | 2015 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; B | 2016 |
Breastfeeding in mothers with systemic lupus erythematosus.
Topics: Adult; Azathioprine; Breast Feeding; Databases, Factual; Decision Making; Female; Humans; Hydroxychl | 2016 |
Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.
Topics: Adult; Animals; Antimalarials; Antiphospholipid Syndrome; Brain; Complement Activation; Complement C | 2016 |
Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes.
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Female; Humans; Hydroxy | 2016 |
The effects of hydroxychloroquine on endothelial dysfunction.
Topics: Antimalarials; Endothelin-1; Female; Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroqu | 2016 |
Reversible ageusia as an adverse effect of hydroxychloroquine treatment.
Topics: Adult; Ageusia; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregna | 2009 |
Cogan's syndrome complicating pregnancy.
Topics: Adult; Anti-Inflammatory Agents; Cogan Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; Preg | 2009 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Antirheumatic Agents; Connective Tissue Diseases; Electroretinography; Evoked Potentials, Visual; Fe | 2009 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Electroretinography; Evoked Potentials, Visual; Female; Humans; Hydroxychloroquine; Infant; Infant, | 2010 |
[Dermatomyositis and pregnancy: a case in Gabon].
Topics: Adult; Antirheumatic Agents; Cesarean Section; Dermatomyositis; Female; Gabon; Glucocorticoids; Huma | 2009 |
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study.
Topics: Autoantigens; Dexamethasone; Drug Therapy, Combination; Female; Heart Block; Heart Defects, Congenit | 2010 |
Systemic lupus erythematosus pregnancies: the Sarawak experience and review of lupus pregnancies in Asia.
Topics: Adult; Antirheumatic Agents; Asia; Cesarean Section; Cross-Sectional Studies; Disease Progression; F | 2011 |
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.
Topics: Antirheumatic Agents; Autoantibodies; Autoantigens; Case-Control Studies; Female; Heart Diseases; Hu | 2010 |
The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine.
Topics: Anterior Eye Segment; Antirheumatic Agents; Arthritis, Rheumatoid; Corneal Opacity; Enzyme Inhibitor | 2011 |
Fetopathy probably associated to self-medication with a blocker of the renin-angiotensin system.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antimalarials; Cesarean | 2011 |
Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.
Topics: Annexin A5; Antibodies, Antiphospholipid; Antibodies, Monoclonal; Antigen-Antibody Complex; Antimala | 2011 |
Prophylactic use of antimalarials during pregnancy.
Topics: Antimalarials; Atovaquone; Chemoprevention; Chloroquine; Doxycycline; Drug Combinations; Female; Hum | 2011 |
[The safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Compl | 2011 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
Topics: Adult; Azathioprine; Biopsy; Child; Cyclophosphamide; Disease Management; Dose-Response Relationship | 2012 |
Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Female; Heart Block; Humans; H | 2013 |
High rate of preterm birth in pregnancies complicated by rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Congenital Abnormalities; Female; Fetal Distress | 2014 |
[Current approaches to prevention and treatment of antiphospholipid syndrome].
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Contraceptives, Oral; Enzyme Inhibitors; | 2003 |
[Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antirheumatic Agents; Azathioprine; Coumarins; Cycloph | 2003 |
Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy.
Topics: Adult; Aspirin; Autoimmune Diseases; Azathioprine; Cyclosporine; Dexamethasone; Female; Hemoglobins; | 2004 |
Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al.
Topics: Autoimmune Diseases; Breast Feeding; Child, Preschool; Electroretinography; Female; Humans; Hydroxyc | 2004 |
Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation.
Topics: Antirheumatic Agents; Breast Feeding; Child Development; Female; Follow-Up Studies; Humans; Hydroxyc | 2005 |
[Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases].
Topics: Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans; Hydroxychloroquine; Infant, Newb | 2006 |
Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents.
Topics: Autoimmune Diseases; Azathioprine; Cyclosporine; Female; Humans; Hydroxychloroquine; Immune System; | 2007 |
Hydroxychloroquine administration in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Hydroxychloroquine; Pregnancy | 1983 |
Systemic lupus erythematosus: important considerations in the adolescent.
Topics: Adolescent; Alopecia; Anxiety; Chronic Disease; Depression; Female; Humans; Hydroxychloroquine; Lupu | 1982 |
Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Follo | 1996 |
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
Topics: Adult; Antirheumatic Agents; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Lupus | 1996 |
The use of hydroxychloroquine in lupus pregnancy: the British experience.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Disc | 1996 |
Antimalarial drugs for rheumatoid disease during pregnancy.
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fetus; Humans; Hydroxychloroquin | 1999 |
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.
Topics: Antirheumatic Agents; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infa | 2001 |
Antimalarial agents in pregnancy.
Topics: Antimalarials; Eye Diseases; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Infant, Newborn; | 2002 |
Evidence of transplacental passage of hydroxychloroquine in humans.
Topics: Adult; Antimalarials; Female; Fetal Blood; Humans; Hydroxychloroquine; Male; Maternal-Fetal Exchange | 2002 |
The treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Child; Chloroquine; Female; Gold; Humans; Hydroxychl | 1977 |
Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience.
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, Systemic; Maryland; Middle A | 1991 |
Pregnancy outcome following first trimester exposure to chloroquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Arthritis, Rheumatoid; Chloro | 1991 |
Assessment of possible drug-resistant Plasmodium falciparum in a pregnant traveller with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Drug Resistance, Microbial; Female; Humans; Hydroxychloroquine; Infant, | 1987 |
Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Topics: Abortion, Spontaneous; Antimalarials; Chloroquine; Female; Fetal Death; Humans; Hydroxychloroquine; | 1988 |
[Effect of plaguenil on fetal and neonatal development (experimental study)].
Topics: Animals; Animals, Newborn; Antimalarials; Embryonic and Fetal Development; Female; Hydroxychloroquin | 1987 |
Hydroxychloroquine in human breast milk.
Topics: Adult; Female; Humans; Hydroxychloroquine; Milk, Human; Pregnancy | 1985 |
Erythropoietic protoporphyria. A clinical study based on 29 cases in 14 families.
Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Child; Child, Preschool; Cholelithiasis; Erythrocytes; | 1974 |
Letter: Absence of chloroquine-induced ototoxicity in a fetus.
Topics: Abnormalities, Drug-Induced; Abortion, Therapeutic; Adult; Ear; Female; Fetus; Humans; Hydroxychloro | 1974 |